

Clinical and Scientific Curriculum of Peter Andreas Fasching, M.D.

Personal Data

Name	Univ.-Prof. Dr. med. Peter Fasching
Place of Birth	May 10, 1975
Nationality	German

Affiliation

Institution	University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg
Institute/Department	Department of Gynecology and Obstetrics
Address	Universitätsstraße 21-23; D-91054 Erlangen, Germany
Phone/FAX	+49-9131-91880611/ +49-9131-91880119
e-mail	peter.fasching@uk-erlangen.de

Education/Training

1986-1993	Episcopal School of Archbishopric Cologne, Germany (Gymnasium), Degree M.A. (Abitur)
1993-1999	Medical School, University of Cologne, Degree M.D.
1996-1999	Doctoral Thesis at the Institute of Pathology, Cologne: PCNA Activity in bone marrow before and after bone marrow transplantation in patients with chronic myelogenous leukemia.
2007	Habilitation (Postdoctoral Lecture Qualification) with the scientific subject: "Risikoeinschätzung für das Mammakarzinom in Prävention und Früherkennung" (Risk assessment for breast cancer patients in prevention and early detection)

Research experience/Academic appointments

2000-2001	Resident Physician, Department Gynecology/Obstetrics, University Hospital Düsseldorf
2001-2006	Resident Physician, Department Gynecology/Obstetrics, University Hospital Erlangen
2006	Board Certification in Gynecology and Obstetrics, Free State of Bavaria, Germany
2006-2008	Attending Physician, Department Gynecology/Obstetrics, University Hospital Erlangen
2008-2011	Research Fellow, Division Hematology/Oncology, UCLA, Los Angeles, USA
since 2011	Associate Professor of Gynecology and Obstetrics, Translational Gynecology and Obstetrics; Department Gynecology/Obstetrics, University Hospital Erlangen, Germany
Since 2022	Awarded Member of the German National Academy of Sciences Leopoldina (https://www.leopoldina.org/mitgliederverzeichnis/mitglieder/member/Member/show/peter-a-fasching/)

Important functions

2001-2008	Head Clinical Trials Unit, Department Gynecology/Obstetrics, University Hospital Erlangen
2002-2008	Head Biomaterial Bank, Department Gynecology/Obstetrics, University Hospital Erlangen, Germany, Germany
Since 2011	Head Clinical Trials Unit, Department Gynecology/Obstetrics, University Hospital Erlangen, Germany
Since 2011	Head Biomaterial Bank, Department Gynecology/Obstetrics, University Hospital Erlangen, Germany
Since 2011	Head Biometrics and Data Management Unit, Department Gynecology/Obstetrics,

	University Hospital Erlangen, Germany
Since 2016	Speaker of the Commission for Translational Research of the Arbeitsgemeinschaft für Gynäkologische Oncology e.V. (A working group of the German Cancer Society)
Since 2019	President of the national AGO-B Breast Cancer Study Group e.V., Germany
Since 2009	Steering Board Member of 6 international Clinical Trials in the field of Breast Cancer (Abrazo, Monaleesa-3, TRIO038, Natalee, Penelope-B)
Since 2020	Member of the Board of Directors of TRIO (Translational Research in Oncology)

Awards

2006	Schmidt-Matthiesen Award of the German Society of Gynecology and Obstetrics
2010	Gunter Bastert Innovation Award of the German Society of Gynecology and Obstetrics
2017	Florence Nightingale Award of the German Society of Breast Diseases
2018	Listed as "Highly Cited Researcher" (https://hcr.clarivate.com/)

Memberships

American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
German Cancer Society (DKG e.V.)
Arbeitsgemeinschaft für Gynäkologische Onkologie (German Society for Gynecologic Cancers, AGO e.V.)
Deutsche Gesellschaft für Senologie (German Breast Cancer Society, DGS e.V.)
AGO-B (Breast Cancer Study Group of the Arbeitsgemeinschaft für Gynäkologische Onkologie, AGO-B e.V.)
Bavarian Society of Gynecology and Obstetrics (BGGF e.V.)
German Society of Gynecology and Obstetrics (DGGG e.V.)

Main funded research projects (each >2 Mio € or USD)

2009-2013	Co-PI: NIH/NHGRI U01 HG005137-01: "Pharmacogenetics of Breast Cancer"
2010-2015	Co-PI: NIH/NIGMS U19GM61388: "Phase II Drug Metabolizing Enzymes"
2014-2017	Co-PI: BMWi 01MT14001E German Ministry for Economic Affairs: "Clinical Data Intelligence"
2018-2022	Co-PI: BMBF 01IS18050B German Science Ministry: "Machine Learning with Knowledge Graphs"
2019-2022	Co-PI: BMG- ZMVI1-2519DAT400 German Ministry of Health: Smart Start. "Digitalization of Pregnancy Care"
2020-2024	Co-PI: BayStmGP: MPG-2008-0003; Bavarian Health Ministry DigiOnko: "Digitalization of Breast Cancer Care"
2020-2023	Co-PI: EU Horizon 2020: RESCUER: "Resistance under Combinational Treatment in ER+ and ER- Breast Cancer"
2020-2023	Co-PI: EU ERA-Net EracoSysMed: "Resistance under Treatment in Breast Cancer"
2020-2024	Co-PI: BayStGP (PBN-MGP-2008-003) DigiOnko – Digital Oncology (Integratives Konzept zur personalisierten Präzisionsmedizin in Prävention, Früh-Erkennung, Therapie und Rückfallvermeidung am Beispiel von Brustkrebs)

Oral presentations at major international conferences

Fasching PA: BRCA mutations, therapy response and prognosis in the neoadjuvant GepearQuinto study
San Antonio Breast Cancer Symposium 2015

Fasching PA: Patient Reported Outcomes in Advanced Breast Cancer Treated With Ribociclib + Fulvestrant: Results from Monaleesa-3
Annual ESMO Meeting 2018

Fasching PA: A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel and Carboplatin Followed by Epirubicin and Cyclophosphamide as Neoadjuvant Chemotherapy in Patients with HER2 Negative Early Breast Cancer and Homologous Recombination Deficiency (HRD)
Annual ASCO Meeting 2019

Fasching PA: Pooled Analysis of Patient-reported Quality of Life in the MONALEESA-2, -3, and -7 Trials of Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-positive, HER2-Negative Advanced Breast Cancer.
Annual ESMO Meeting 2020

5 selected full publications as first or last author (selected from 630 pubmed listed publications)

Fasching PA, Liu D, Scully S et al. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. *Clin Cancer Res* 2022; 28: 3342-3355. DOI: 10.1158/1078-0432.CCR-20-4774

Fasching PA, Yadav S, Hu C, Wunderle M, Haberle L, Hart SN, et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
J Clin Oncol. 2021; 39: 1619-1630.

Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Ann Oncol. 2021;32:49-57.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GepearQuinto Study.
J Clin Oncol. 2018;36:2281-7.

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, **Fasching PA:** Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
J Clin Oncol. 2015;33:304-11.

Complete list of PubMed listed publications as first author, last author or co-author (newest first)

- Web of Science Researcher ID: <https://www.webofscience.com/wos/author/record/ABH-9912-2020>
- H-Index as of October 2022: 87
- 6 times: New England Journal of Medicine:
- One time: Lancet
- 7 times: Lancet Oncology
- 3 times: Nature
- One time: JAMA
- 7 times: JAMA Oncology
- 23 times: Nature Genetics
- 15 times: Journal of Clinical Oncology
- 21 times: Annals of Oncology

- 1 Ditsch N, Wocke A, Untch M et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. *Breast Care (Basel)* 2022; 17: 403-420. DOI: 10.1159/000524879
- 2 Thill M, Luftner D, Kolberg-Liedtke C et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. *Breast Care (Basel)* 2022; 17: 421-429. DOI: 10.1159/000524789
- 3 Fehm TN, Welslau M, Muller V et al. Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: 912-921. DOI: 10.1055/a-1912-7105
- 4 Aktas B, Fehm TN, Welslau M et al. Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: 922-931. DOI: 10.1055/a-1912-7362
- 5 Gonzalez-Martin A, Desauw C, Heitz F et al. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. *Eur J Cancer* 2022; 174: 221-231. DOI: 10.1016/j.ejca.2022.07.022
- 6 Trapp EK, Fasching PA, Fehm T et al. Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial. *Cancers (Basel)* 2022; 14. DOI: 10.3390/cancers14163949
- 7 Loibl S, Schneeweiss A, Huober J et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. *Ann Oncol* 2022. DOI: 10.1016/j.annonc.2022.07.1940
- 8 Kolberg-Liedtke C, Luftner D, Brucker SY et al. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. *Breast Care (Basel)* 2022; 17: 336-345. DOI: 10.1159/000517501
- 9 Erber R, Angeloni M, Stohr R et al. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *Int J Mol Sci* 2022; 23. DOI: 10.3390/ijms23158716
- 10 Grootes I, Keeman R, Blows FM et al. Incorporating progesterone receptor expression into the PRE-DICT breast prognostic model. *Eur J Cancer* 2022; 173: 178-193. DOI: 10.1016/j.ejca.2022.06.011
- 11 Welslau M, Muller V, Luftner D et al. Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: 580-589. DOI: 10.1055/a-1811-6106
- 12 Muller V, Welslau M, Luftner D et al. Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: 590-600. DOI: 10.1055/a-1811-6148
- 13 Flaucher M, Nissen M, Jaeger KM et al. Smartphone-Based Colorimetric Analysis of Urine Test Strips for At-Home Prenatal Care. *IEEE J Transl Eng Health Med* 2022; 10: 2800109. DOI: 10.1109/JTEHM.2022.3179147

- 14 Muller V, Hein A, Hartkopf AD et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. *Eur J Cancer* 2022; 172: 13-21. DOI: 10.1016/j.ejca.2022.05.015
- 15 Schneider MO, Pretschner J, Goecke TW et al. Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy. *Arch Gynecol Obstet* 2022. DOI: 10.1007/s00404-022-06644-8
- 16 Fasching PA, Liu D, Scully S et al. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. *Clin Cancer Res* 2022; 28: 3342-3355. DOI: 10.1158/1078-0432.CCR-20-4774
- 17 Loibl S, Untch M, Burchardi N et al. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. *Ann Oncol* 2022; 33: 743-744. DOI: 10.1016/j.annonc.2022.04.003
- 18 Blohmer JU, Link T, Reinisch M et al. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 x 2 Randomized Clinical Trial. *JAMA Oncol* 2022; 8: 1010-1018. DOI: 10.1001/jamaoncol.2022.1059
- 19 Dorling L, Carvalho S, Allen J et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. *Genome Med* 2022; 14: 51. DOI: 10.1186/s13073-022-01052-8
- 20 Chen H, Fan S, Stone J et al. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. *Breast Cancer Res* 2022; 24: 27. DOI: 10.1186/s13058-022-01524-0
- 21 Huebner H, Haberle L, Muller V et al. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. *Cancers (Basel)* 2022; 14. DOI: 10.3390/cancers14071721
- 22 Luftner D, Fasching PA, Haidinger R et al. ABC6 Consensus: Assessment by a Group of German Experts. *Breast Care (Basel)* 2022; 17: 90-100. DOI: 10.1159/000522068
- 23 Roetner J, Petry J, Niekamp J et al. [Maternal depression and child development: A prospective analysis of consequences, risk and protective factors]. *Z Kinder Jugendpsychiatr Psychother* 2022; 50: 382-394. DOI: 10.1024/1422-4917/a000866
- 24 Dareng EO, Tyrer JP, Barnes DR et al. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet* 2022; 30: 630-631. DOI: 10.1038/s41431-022-01085-y
- 25 Luftner D, Schutz F, Stickeler E et al. Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: e1. DOI: 10.1055/a-1784-9971
- 26 Nissen M, Slim S, Jager K et al. Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study. *JMIR Form Res* 2022; 6: e33635. DOI: 10.2196/33635
- 27 de Gregorio A, Janni W, Friedl TWP et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. *Br J Cancer* 2022; 126: 1715-1724. DOI: 10.1038/s41416-021-01690-6
- 28 Hein A, Kehl S, Haberle L et al. Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnancy and at birth in Franconia). *Geburtshilfe Frauenheilkd* 2022; 82: 226-234. DOI: 10.1055/a-1727-9672
- 29 Luftner D, Schutz F, Stickeler E et al. Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2022; 82: 215-225. DOI: 10.1055/a-1724-9569
- 30 Thomssen C, Fehm TN, Stickeler E et al. Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. *Geburtshilfe Frauenheilkd* 2022; 82: 206-214. DOI: 10.1055/a-1724-9639
- 31 Gerber B, Schneeweiss A, Mobus V et al. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. *Cancers (Basel)* 2022; 14. DOI: 10.3390/cancers14030521

- 32 Ramachandran D, Dennis J, Fachal L et al. Genome-wide association study and functional follow-up identify 14q12 as a candidate risk locus for cervical cancer. *Hum Mol Genet* 2022; 31: 2483-2497. DOI: 10.1093/hmg/ddac031
- 33 Schmid P, Cortes J, Dent R et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med* 2022; 386: 556-567. DOI: 10.1056/NEJMoa2112651
- 34 Graf J, Sickenberger N, Brusniak K et al. Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. *J Med Internet Res* 2022; 24: e16128. DOI: 10.2196/16128
- 35 Huang M, Haiderali A, Fox GE et al. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. *Pharmacoeconomics* 2022; 40: 519-558. DOI: 10.1007/s40273-021-01121-7
- 36 Peddi PF, Fasching PA, Liu D et al. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. *Clin Cancer Res* 2022; 28: 1854-1862. DOI: 10.1158/1078-0432.CCR-21-1762
- 37 Breast Cancer Association C, Mavaddat N, Dorling L et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. *JAMA Oncol* 2022; 8: e216744. DOI: 10.1001/jamaoncol.2021.6744
- 38 Dennis J, Tyrer JP, Walker LC et al. Rare germline copy number variants (CNVs) and breast cancer risk. *Commun Biol* 2022; 5: 65. DOI: 10.1038/s42003-021-02990-6
- 39 Jerusalem G, Delea TE, Martin M et al. Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR+/-HER2- Advanced Breast Cancer in the MONALEESA-3 Trial. *Clin Breast Cancer* 2022; 22: 326-335. DOI: 10.1016/j.clbc.2021.12.008
- 40 Dareng EO, Tyrer JP, Barnes DR et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet* 2022; 30: 349-362. DOI: 10.1038/s41431-021-00987-7
- 41 Ahearn TU, Zhang H, Michailidou K et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. *Breast Cancer Res* 2022; 24: 2. DOI: 10.1186/s13058-021-01484-x
- 42 Plank AC, Maschke J, Rohleder N et al. Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents. *Front Immunol* 2021; 12: 795580. DOI: 10.3389/fimmu.2021.795580
- 43 Muller V, Banys-Paluchowski M, Friedl TWP et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. *ESMO Open* 2021; 6: 100299. DOI: 10.1016/j.esmoop.2021.100299
- 44 Nabieva N, Fasching PA. Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. *Cancers (Basel)* 2021; 13. DOI: 10.3390/cancers13225643
- 45 Schneeweiss A, Michel LL, Mobus V et al. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. *Eur J Cancer* 2022; 160: 100-111. DOI: 10.1016/j.ejca.2021.10.011
- 46 Kang EY, Millstein J, Popovic G et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Arch* 2022; 480: 855-871. DOI: 10.1007/s00428-021-03232-0
- 47 Erber R, Kailayangiri S, Huebner H et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. *Cancers (Basel)* 2021; 13. DOI: 10.3390/cancers13215577
- 48 Fasching PA, Delea TE, Lu YS et al. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/-HER2- Advanced Breast Cancer. *Cancer Manag Res* 2021; 13: 8179-8189. DOI: 10.2147/CMAR.S325043
- 49 Friedrich M, Kuhn T, Janni W et al. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. *Geburtshilfe Frauenheilkd* 2021; 81: e31. DOI: 10.1055/a-1674-1114

- 50 Harbeck N, Rastogi P, Martin M et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol* 2021; 32: 1571-1581. DOI: 10.1016/j.annonc.2021.09.015
- 51 Konecny GE, Hendrickson AEW, Davidson TM et al. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. *Gynecol Oncol* 2021; 163: 465-472. DOI: 10.1016/j.ygyno.2021.09.025
- 52 Friedrich M, Kuhn T, Janni W et al. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. *Geburtshilfe Frauenheilkd* 2021; 81: 1112-1120. DOI: 10.1055/a-1499-8431
- 53 Schneeweiss A, Fasching PA, Fehm T et al. AGO Algorithms for the Treatment of Breast Cancer: Update 2021. *Geburtshilfe Frauenheilkd* 2021; 81: 1101-1111. DOI: 10.1055/a-1519-7089
- 54 Hurvitz SA, McAndrew NP, Bardia A et al. A careful reassessment of anthracycline use in curable breast cancer. *NPJ Breast Cancer* 2021; 7: 134. DOI: 10.1038/s41523-021-00342-5
- 55 Escala-Garcia M, Canisius S, Keeman R et al. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Sci Rep* 2021; 11: 19787. DOI: 10.1038/s41598-021-99409-3
- 56 Erber R, Hartmann A, Fasching PA et al. Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer-A Europe-Wide External Quality Assessment. *Cancers (Basel)* 2021; 13. DOI: 10.3390/cancers13184718
- 57 Sturken C, Mobus V, Milde-Langosch K et al. Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. *BMC Cancer* 2021; 21: 1024. DOI: 10.1186/s12885-021-08754-z
- 58 Llop-Guevara A, Loibl S, Villacampa G et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. *Ann Oncol* 2021; 32: 1590-1596. DOI: 10.1016/j.annonc.2021.09.003
- 59 Huebner H, Lubrich H, Blum S et al. Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. *Reprod Biomed Online* 2021; 43: 788-798. DOI: 10.1016/j.rbmo.2021.08.004
- 60 Jank P, Gehlhaar C, Lederer B et al. Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. *PLoS One* 2021; 16: e0257142. DOI: 10.1371/journal.pone.0257142
- 61 Blum S, Fasching PA, Hildebrandt T et al. Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. *Arch Gynecol Obstet* 2022; 305: 977-984. DOI: 10.1007/s00404-021-06200-w
- 62 Slamon DJ, Neven P, Chia S et al. Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]. *Ann Oncol* 2021; 32: 1307. DOI: 10.1016/j.annonc.2021.07.011
- 63 Morra A, Escala-Garcia M, Beesley J et al. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Res* 2021; 23: 86. DOI: 10.1186/s13058-021-01450-7
- 64 Sturken C, Mobus V, Milde-Langosch K et al. TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. *BMC Cancer* 2021; 21: 920. DOI: 10.1186/s12885-021-08656-0
- 65 Maschke J, Roetner J, Bosl S et al. Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. *Int J Environ Res Public Health* 2021; 18. DOI: 10.3390/ijerph18157920
- 66 Ruth KS, Day FR, Hussain J et al. Genetic insights into biological mechanisms governing human ovarian ageing. *Nature* 2021; 596: 393-397. DOI: 10.1038/s41586-021-03779-7

- 67 Park HA, Neumeyer S, Michailidou K et al. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *Br J Cancer* 2021; 125: 1135-1145. DOI: 10.1038/s41416-021-01432-8
- 68 Hein A, Hartkopf AD, Emons J et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. *Eur J Cancer* 2021; 155: 1-12. DOI: 10.1016/j.ejca.2021.06.033
- 69 Hartkopf AD, Brucker SY, Taran FA et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. *Eur J Cancer* 2021; 154: 128-137. DOI: 10.1016/j.ejca.2021.06.028
- 70 Denkert C, Seither F, Schneeweiss A et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. *Lancet Oncol* 2021; 22: 1151-1161. DOI: 10.1016/S1470-2045(21)00301-6
- 71 Lux MP, Wasner S, Meyer J et al. Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. *Breast Care (Basel)* 2021; 16: 291-298. DOI: 10.1159/000509127
- 72 Wunderle M, Haberle L, Hein A et al. Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. *Breast Care (Basel)* 2021; 16: 254-262. DOI: 10.1159/000507475
- 73 Thill M, Friedrich M, Kolberg-Liedtke C et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16: 228-235. DOI: 10.1159/000516420
- 74 Ditsch N, Kolberg-Liedtke C, Friedrich M et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16: 214-227. DOI: 10.1159/000516419
- 75 Marme F, Solbach C, Michel L et al. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 153: 203-212. DOI: 10.1016/j.ejca.2021.05.027
- 76 Reimann H, Nguyen A, Sanborn JZ et al. Identification and validation of expressed HLA-binding breast cancer neopeptides for potential use in individualized cancer therapy. *J Immunother Cancer* 2021; 9. DOI: 10.1136/jitc-2021-002605
- 77 Theuser AK, Hack CC, Fasching PA et al. Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. *Geburtshilfe Frauenheilkd* 2021; 81: 699-707. DOI: 10.1055/a-1487-6284
- 78 Fehm TN, Stickeler E, Fasching PA et al. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. *Geburtshilfe Frauenheilkd* 2021; 81: 654-665. DOI: 10.1055/a-1487-7642
- 79 Untch M, Fasching PA, Brucker SY et al. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. *Geburtshilfe Frauenheilkd* 2021; 81: 637-653. DOI: 10.1055/a-1483-2782
- 80 Friedl TWP, Fehm T, Muller V et al. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7: 1149-1157. DOI: 10.1001/jamaoncol.2021.1854
- 81 Quinn MCJ, McCue K, Shi W et al. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev* 2021; 30: 1669-1680. DOI: 10.1158/1055-9965.EPI-20-1817
- 82 Heindl F, Fasching PA, Hein A et al. Mammographic density and prognosis in primary breast cancer patients. *Breast* 2021; 59: 51-57. DOI: 10.1016/j.breast.2021.06.004
- 83 Baxter JS, Johnson N, Tomczyk K et al. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *Am J Hum Genet* 2021; 108: 1190-1203. DOI: 10.1016/j.ajhg.2021.05.013

- 84 Furlanetto J, Marme F, Seiler S et al. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. *Eur J Cancer* 2021; 152: 193-203. DOI: 10.1016/j.ejca.2021.04.038
- 85 Slamon DJ, Neven P, Chia S et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. *Ann Oncol* 2021; 32: 1015-1024. DOI: 10.1016/j.annonc.2021.05.353
- 86 Gelmon KA, Fasching PA, Couch FJ et al. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. *Eur J Cancer* 2021; 152: 68-77. DOI: 10.1016/j.ejca.2021.03.029
- 87 Park J, Choi JY, Choi J et al. Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies? *Cancers (Basel)* 2021; 13. DOI: 10.3390/cancers13102370
- 88 Ditsch N, Stickeler E, Behrens A et al. Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers. *Geburtshilfe Frauenheilkd* 2021; 81: 539-548. DOI: 10.1055/a-1464-1221
- 89 Stickeler E, Aktas B, Behrens A et al. Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. *Geburtshilfe Frauenheilkd* 2021; 81: 526-538. DOI: 10.1055/a-1464-0953
- 90 Luftner D, Hartkopf AD, Lux MP et al. Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. *Breast Care (Basel)* 2021; 16: 108-114. DOI: 10.1159/000515701
- 91 Coignard J, Lush M, Beesley J et al. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nat Commun* 2021; 12: 2986. DOI: 10.1038/s41467-021-23162-4
- 92 Zhu J, O'Mara TA, Liu D et al. Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. *Cancers (Basel)* 2021; 13. DOI: 10.3390/cancers13092088
- 93 Ramachandran D, Wang Y, Schurmann P et al. Association of genomic variants at PAX8 and PBX2 with cervical cancer risk. *Int J Cancer* 2021. DOI: 10.1002/ijc.33614
- 94 Lux MP, Schneeweiss A, Hartkopf AD et al. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. *Geburtshilfe Frauenheilkd* 2021; 81: 469-480. DOI: 10.1055/a-1397-7170
- 95 Fasching PA, Yadav S, Hu C et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. *J Clin Oncol* 2021; 39: 1619-1630. DOI: 10.1200/JCO.20.01200
- 96 Villegas SL, Nekljudova V, Pfarr N et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. *Eur J Cancer* 2021; 148: 159-170. DOI: 10.1016/j.ejca.2021.02.020
- 97 Theuser AK, Antoniadis S, Langemann H et al. Active Participation, Mind-Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. *Integr Cancer Ther* 2021; 20: 1534735421990108. DOI: 10.1177/1534735421990108
- 98 Coignard J, Lush M, Beesley J et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nat Commun* 2021; 12: 1078. DOI: 10.1038/s41467-020-20496-3
- 99 Sinn BV, Loibl S, Hanusch CA et al. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. *Clin Cancer Res* 2021; 27: 2584-2591. DOI: 10.1158/1078-0432.CCR-20-3113
- 100 Maschke J, Roetner J, Goecke TW et al. Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. *Brain Sci* 2021; 11. DOI: 10.3390/brainsci11020154
- 101 Laakmann E, Witzel I, Neunhoffer T et al. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. *Cancers (Basel)* 2020; 12. DOI: 10.3390/cancers12102787

- 102 Emons J, Fasching PA, Wunderle M et al. Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. *Ther Adv Med Oncol* 2020; 12: 1758835920957932. DOI: 10.1177/1758835920957932
- 103 Erber R, Meyer J, Taubert H et al. PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. *Cancers (Basel)* 2020; 12. DOI: 10.3390/cancers12102742
- 104 Wuerfel FM, Huebner H, Haberle L et al. HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. *Sci Rep* 2020; 10: 15750. DOI: 10.1038/s41598-020-72837-3
- 105 Schneeweiss A, Ettl J, Luftner D et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. *Breast* 2020; 54: 88-95. DOI: 10.1016/j.breast.2020.08.011
- 106 Huang M, O'Shaughnessy J, Zhao J et al. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. *Cancer Res* 2020; 80: 5427-5434. DOI: 10.1158/0008-5472.CAN-20-1792
- 107 Hester A, Gass P, Fasching PA et al. Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres. *Geburtshilfe Frauenheilkd* 2020; 80: 924-931. DOI: 10.1055/a-1226-6666
- 108 Schneider MO, Hubner T, Pretscher J et al. Genetic variants in the glucocorticoid pathway genes and birth weight. *Arch Gynecol Obstet* 2021; 303: 427-434. DOI: 10.1007/s00404-020-05761-6
- 109 Erber R, Rubner M, Davenport S et al. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. *Breast Cancer Res Treat* 2020; 184: 311-324. DOI: 10.1007/s10549-020-05865-2
- 110 Kho PF, Amant F, Annibaldi D et al. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. *Int J Cancer* 2021; 148: 307-319. DOI: 10.1002/ijc.33206
- 111 Jank P, Gehlhaar C, Bianca L et al. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. *PLoS One* 2020; 15: e0238021. DOI: 10.1371/journal.pone.0238021
- 112 Mijnes J, Tiedemann J, Eschenbruch J et al. Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. *Oncotarget* 2020; 11: 2958. DOI: 10.18632/oncotarget.27685
- 113 Ditsch N, Untch M, Kolberg-Liedtke C et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. *Breast Care (Basel)* 2020; 15: 294-309. DOI: 10.1159/000508736
- 114 Huang M, O'Shaughnessy J, Zhao J et al. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. *J Natl Compr Canc Netw* 2020; 18: 1096-1104. DOI: 10.6004/jnccn.2020.7550
- 115 Vasileiou G, Costa MJ, Long C et al. Breast MRI texture analysis for prediction of BRCA-associated genetic risk. *BMC Med Imaging* 2020; 20: 86. DOI: 10.1186/s12880-020-00483-2
- 116 Kang EY, Cheasley D, LePage C et al. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Mod Pathol* 2021; 34: 194-206. DOI: 10.1038/s41379-020-0618-9
- 117 Kungl MT, Rutherford HJ, Heinisch C et al. Does anxiety impact the neural processing of child faces in mothers of school-aged children? An ERP study using an emotional Go/NoGo task. *Soc Neurosci* 2020; 15: 530-543. DOI: 10.1080/17470919.2020.1788988
- 118 Stonawski V, Roetner J, Goecke TW et al. Genome-Wide DNA Methylation Patterns in Children Exposed to Nonpharmacologically Treated Prenatal Depressive Symptoms: Results From 2 Independent Cohorts. *Epigenet Insights* 2020; 13: 2516865720932146. DOI: 10.1177/2516865720932146
- 119 Ramachandran D, Schurmann P, Mao Q et al. Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. *Int J Cancer* 2020; 147: 2458-2468. DOI: 10.1002/ijc.33171

- 120 Untch M, Wurstlein R, Luftner D et al. ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. *Geburtshilfe Frauenheilkd* 2020; 80: 588-600. DOI: 10.1055/a-1139-9380
- 121 Martins FC, Couturier DL, Paterson A et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *Br J Cancer* 2020; 123: 793-802. DOI: 10.1038/s41416-020-0900-0
- 122 Talhouk A, George J, Wang C et al. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clin Cancer Res* 2020; 26: 5411-5423. DOI: 10.1158/1078-0432.CCR-20-0103
- 123 Liu J, Prager-van der Smissen WJC, Collee JM et al. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Sci Rep* 2020; 10: 9688. DOI: 10.1038/s41598-020-65665-y
- 124 Hack CC, Wasner S, Meyer J et al. Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. *Complement Med Res* 2020; 27: 431-439. DOI: 10.1159/000508235
- 125 Millstein J, Budden T, Goode EL et al. Prognostic gene expression signature for high-grade serous ovarian cancer. *Ann Oncol* 2020; 31: 1240-1250. DOI: 10.1016/j.annonc.2020.05.019
- 126 Morra A, Jung AY, Behrens S et al. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 2021; 30: 623-642. DOI: 10.1158/1055-9965.EPI-20-0924
- 127 Johnson N, Maguire S, Morra A et al. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *Br J Cancer* 2021; 124: 842-854. DOI: 10.1038/s41416-020-01185-w
- 128 Rugo HS, Im SA, Cardoso F et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7: 573-584. DOI: 10.1001/jamaoncol.2020.7932
- 129 Breast Cancer Association C, Dorling L, Carvalho S et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med* 2021; 384: 428-439. DOI: 10.1056/NEJMoa1913948
- 130 Furlanetto J, Mobus V, Schneeweiss A et al. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 145: 44-52. DOI: 10.1016/j.ejca.2020.12.007
- 131 Denkert C, Untch M, Benz S et al. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy(small star, filled). *Ann Oncol* 2021; 32: 500-511. DOI: 10.1016/j.annonc.2020.12.016
- 132 Schneeweiss A, Ettl J, Luftner D et al. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". *Breast* 2021; 55: 138-139. DOI: 10.1016/j.breast.2020.12.007
- 133 Laakmann E, Emons J, Taran FA et al. Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. *Geburtshilfe Frauenheilkd* 2020; 80: e289. DOI: 10.1055/a-1306-7231
- 134 Massa C, Karn T, Denkert C et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. *J Immunother Cancer* 2020; 8. DOI: 10.1136/jitc-2020-001261
- 135 Ruger AM, Schneeweiss A, Seiler S et al. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. *J Am Heart Assoc* 2020; 9: e018143. DOI: 10.1161/JAHA.120.018143
- 136 Huebner H, Kurbacher CM, Kuesters G et al. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. *BMC Cancer* 2020; 20: 1091. DOI: 10.1186/s12885-020-07546-1

- 137 Laakmann E, Emons J, Taran FA et al. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. *Geburtshilfe Frauenheilkd* 2020; 80: 1134-1142. DOI: 10.1055/a-1286-2917
- 138 Wurfel FM, Wirtz RM, Winterhalter C et al. HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80: 1123-1133. DOI: 10.1055/a-1128-6664
- 139 Tesch H, Muller V, Wockel A et al. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80: 1115-1122. DOI: 10.1055/a-1270-7481
- 140 Huober J, Schneeweiss A, Hartkopf AD et al. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80: 1105-1114. DOI: 10.1055/a-1270-7208
- 141 Ruddy KJ, Schaid DJ, Batzler A et al. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. *J Natl Cancer Inst* 2021; 113: 1105-1108. DOI: 10.1093/jnci/djaa160
- 142 Glubb DM, Thompson DJ, Aben KKH et al. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiol Biomarkers Prev* 2021; 30: 217-228. DOI: 10.1158/1055-9965.EPI-20-0739
- 143 Fasching PA, Link T, Hauke J et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol* 2021; 32: 49-57. DOI: 10.1016/j.annonc.2020.10.471
- 144 de Gregorio A, Haberle L, Fasching PA et al. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22: 111. DOI: 10.1186/s13058-020-01348-w
- 145 Michel LL, Hartkopf AD, Fasching PA et al. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. *Cancers (Basel)* 2020; 12. DOI: 10.3390/cancers12103021
- 146 Fasching PA, Beck JT, Chan A et al. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. *Breast* 2020; 54: 148-154. DOI: 10.1016/j.breast.2020.09.008
- 147 Kramer I, Hoening MJ, Mavaddat N et al. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *Am J Hum Genet* 2020; 107: 837-848. DOI: 10.1016/j.ajhg.2020.09.001
- 148 Grimm J, Stemmler M, Golub Y et al. The association between prenatal alcohol consumption and preschool child stress system disturbance. *Dev Psychobiol* 2021; 63: 687-697. DOI: 10.1002/dev.22038
- 149 Schroth W, Buttner FA, Kandabarau S et al. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. *Clin Cancer Res* 2020; 26: 6523-6534. DOI: 10.1158/1078-0432.CCR-20-1923
- 150 Pretscher J, Ruebner M, Ekici AB et al. Genetic variations in estrogen and progesterone pathway genes in preeclampsia patients and controls in Bavaria. *Arch Gynecol Obstet* 2021; 303: 897-904. DOI: 10.1007/s00404-020-05812-y
- 151 Karn T, Denkert C, Weber KE et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. *Ann Oncol* 2020; 31: 1216-1222. DOI: 10.1016/j.annonc.2020.05.015
- 152 Zhang H, Ahearn TU, Lecarpentier J et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet* 2020; 52: 572-581. DOI: 10.1038/s41588-020-0609-2
- 153 Kapoor PM, Mavaddat N, Choudhury PP et al. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *J Natl Cancer Inst* 2021; 113: 329-337. DOI: 10.1093/jnci/djaa056
- 154 Luftner D, Schneeweiss A, Hartkopf AD et al. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. *Geburtshilfe Frauenheilkd* 2020; 80: 391-398. DOI: 10.1055/a-1111-8775

- 155 Stumpfe FM, Titzmann A, Schneider MO et al. SARS-CoV-2 Infection in Pregnancy - a Review of the Current Literature and Possible Impact on Maternal and Neonatal Outcome. *Geburtshilfe Frauenheilkd* 2020; 80: 380-390. DOI: 10.1055/a-1134-5951
- 156 Giardiello D, Hauptmann M, Steyerberg EW et al. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. *Breast Cancer Res Treat* 2020; 181: 423-434. DOI: 10.1007/s10549-020-05611-8
- 157 Loehberg CR, Meyer J, Haberle L et al. Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center. *Arch Gynecol Obstet* 2020; 301: 1299-1306. DOI: 10.1007/s00404-020-05525-2
- 158 Robertson JFR, Evans A, Henschen S et al. A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER(+) HER2(-) Primary Breast Cancer. *Clin Cancer Res* 2020; 26: 4242-4249. DOI: 10.1158/1078-0432.CCR-19-3387
- 159 Untch M, Loibl S, Fasching PA. Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. *Breast Care* 2019; Doi 10.1159/000500620. *Breast Care (Basel)* 2020; 15: 96-101. DOI: 10.1159/000500624
- 160 Thomssen C, Luftner D, Untch M et al. International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. *Breast Care (Basel)* 2020; 15: 82-95. DOI: 10.1159/000505957
- 161 Wunderle M, Ruebner M, Haberle L et al. RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. *Sci Rep* 2020; 10: 5171. DOI: 10.1038/s41598-020-62070-3
- 162 Werutsky G, Untch M, Hanusch C et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. *Eur J Cancer* 2020; 130: 92-101. DOI: 10.1016/j.ejca.2020.02.015
- 163 Pohl-Rescigno E, Hauke J, Loibl S et al. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. *JAMA Oncol* 2020; 6: 744-748. DOI: 10.1001/jamaoncol.2020.0007
- 164 Schneeweiss A, Hartkopf AD, Muller V et al. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. *Geburtshilfe Frauenheilkd* 2020; 80: 277-287. DOI: 10.1055/a-1111-2431
- 165 Feng H, Gusev A, Pasaniuc B et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet Epidemiol* 2020; 44: 442-468. DOI: 10.1002/gepi.22288
- 166 Schmid P, Cortes J, Puztai L et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med* 2020; 382: 810-821. DOI: 10.1056/NEJMoa1910549
- 167 Ingle JN, Cairns J, Suman VJ et al. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor alpha. *Clin Cancer Res* 2020; 26: 2986-2996. DOI: 10.1158/1078-0432.CCR-19-3091
- 168 Ellmann S, Wenkel E, Dietzel M et al. Implementation of machine learning into clinical breast MRI: Potential for objective and accurate decision-making in suspicious breast masses. *PLoS One* 2020; 15: e0228446. DOI: 10.1371/journal.pone.0228446
- 169 Rauch T, Rieger J, Pelzer G et al. Discrimination analysis of breast calcifications using x-ray dark-field radiography. *Med Phys* 2020; 47: 1813-1826. DOI: 10.1002/mp.14043
- 170 Hack CC, Haberle L, Brucker SY et al. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. *Breast* 2020; 50: 11-18. DOI: 10.1016/j.breast.2019.12.017
- 171 Escala-Garcia M, Abraham J, Andrulis IL et al. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nat Commun* 2020; 11: 312. DOI: 10.1038/s41467-019-14100-6

- 172 Karn T, Meissner T, Weber KE et al. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. *Clin Cancer Res* 2020; 26: 1896-1904. DOI: 10.1158/1078-0432.CCR-19-1954
- 173 Fachal L, Aschard H, Beesley J et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet* 2020; 52: 56-73. DOI: 10.1038/s41588-019-0537-1
- 174 Hartkopf AD, Muller V, Wockel A et al. Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. *Geburtshilfe Frauenheilkd* 2019; 79: 1309-1319. DOI: 10.1055/a-1039-4458
- 175 Hein A, Schneider MO, Renner SK et al. Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. *Arch Gynecol Obstet* 2020; 301: 289-294. DOI: 10.1007/s00404-019-05414-3
- 176 Giardiello D, Steyerberg EW, Hauptmann M et al. Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Res* 2019; 21: 144. DOI: 10.1186/s13058-019-1221-1
- 177 Sinn BV, Weber KE, Schmitt WD et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. *Breast Cancer Res* 2019; 21: 142. DOI: 10.1186/s13058-019-1231-z
- 178 Slamon DJ, Neven P, Chia S et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. *N Engl J Med* 2020; 382: 514-524. DOI: 10.1056/NEJMoa1911149
- 179 Luftner D, Bauerfeind I, Braun M et al. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). *Breast Care (Basel)* 2019; 14: 315-324. DOI: 10.1159/000502603
- 180 Mijnes J, Tiedemann J, Eschenbruch J et al. SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. *Oncotarget* 2019; 10: 6494-6508. DOI: 10.18632/oncotarget.27303
- 181 Witzel I, Loibl S, Wirtz R et al. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. *Br J Cancer* 2019; 121: 1009-1015. DOI: 10.1038/s41416-019-0630-3
- 182 Figlioli G, Bogliolo M, Catucci I et al. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer* 2019; 5: 38. DOI: 10.1038/s41523-019-0127-5
- 183 Franken A, Honisch E, Reinhardt F et al. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. *J Mol Diagn* 2020; 22: 111-121. DOI: 10.1016/j.jmoldx.2019.09.004
- 184 Welslau M, Hartkopf AD, Muller V et al. Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2019; 79: 1090-1099. DOI: 10.1055/a-1001-9952
- 185 Schutz F, Fasching PA, Welslau M et al. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2019; 79: 1079-1089. DOI: 10.1055/a-1001-9925
- 186 Thill M, Jackisch C, Janni W et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. *Breast Care (Basel)* 2019; 14: 247-255. DOI: 10.1159/000500999
- 187 Ditsch N, Untch M, Thill M et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. *Breast Care (Basel)* 2019; 14: 224-245. DOI: 10.1159/000501000
- 188 Jiang X, Finucane HK, Schumacher FR et al. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. *Nat Commun* 2019; 10: 4386. DOI: 10.1038/s41467-019-12095-8
- 189 Dork T, Peterlongo P, Mannermaa A et al. Two truncating variants in FANCC and breast cancer risk. *Sci Rep* 2019; 9: 12524. DOI: 10.1038/s41598-019-48804-y

- 190 Schink M, Konturek PC, Herbert SL et al. Different nutrient intake and prevalence of gastrointestinal comorbidities in women with endometriosis. *J Physiol Pharmacol* 2019; 70. DOI: 10.26402/jpp.2019.2.09
- 191 Ruddy KJ, Schaid DJ, Partridge AH et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. *Fertil Steril* 2019; 112: 731-739 e731. DOI: 10.1016/j.fertnstert.2019.05.018
- 192 Furlanetto J, von Minckwitz G, Lederer B et al. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. *Breast Cancer* 2019; 26: 826-834. DOI: 10.1007/s12282-019-00990-3
- 193 Ooi BNS, Loh H, Ho PJ et al. The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. *Int J Epidemiol* 2019; 48: 781-794. DOI: 10.1093/ije/dyz124
- 194 Golub Y, Kuitunen-Paul S, Panaseth K et al. Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6-9-year old children. *Physiol Behav* 2019; 209: 112584. DOI: 10.1016/j.physbeh.2019.112584
- 195 Wallwiener M, Nabieva N, Feisst M et al. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. *BMC Cancer* 2019; 19: 611. DOI: 10.1186/s12885-019-5806-y
- 196 Schneeweiss A, Denkert C, Fasching PA et al. Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. *Geburtshilfe Frauenheilkd* 2019; 79: 605-617. DOI: 10.1055/a-0887-0285
- 197 Untch M, Thomssen C, Bauerfeind I et al. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). *Geburtshilfe Frauenheilkd* 2019; 79: 591-604. DOI: 10.1055/a-0897-6457
- 198 Trapp E, Janni W, Schindlbeck C et al. Response to Di Cosimo, Torri, and Porcu. *J Natl Cancer Inst* 2019; 111: 1234-1235. DOI: 10.1093/jnci/djz095
- 199 Hurvitz SA, Martin M, Jung KH et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. *J Clin Oncol* 2019; 37: 2206-2216. DOI: 10.1200/JCO.19.00882
- 200 Burghaus S, Hildebrandt T, Fahlbusch C et al. Standards Used by a Clinical and Scientific Endometriosis Center for the Diagnosis and Therapy of Patients with Endometriosis. *Geburtshilfe Frauenheilkd* 2019; 79: 487-497. DOI: 10.1055/a-0813-4411
- 201 Kolberg HC, Schneeweiss A, Fehm TN et al. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. *Geburtshilfe Frauenheilkd* 2019; 79: 470-482. DOI: 10.1055/a-0887-0861
- 202 Vachon CM, Scott CG, Tamimi RM et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. *Breast Cancer Res* 2019; 21: 68. DOI: 10.1186/s13058-019-1138-8
- 203 Loibl S, Untch M, Burchardi N et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol* 2019; 30: 1279-1288. DOI: 10.1093/annonc/mdz158
- 204 Untch M, Jackisch C, Schneeweiss A et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. *J Clin Oncol* 2019; 37: 2226-2234. DOI: 10.1200/JCO.18.01842
- 205 Laakmann E, Witzel I, Fasching PA et al. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. *Breast Cancer Res* 2019; 21: 60. DOI: 10.1186/s13058-019-1144-x
- 206 Denkert C, Budczies J, Regan MM et al. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance

- in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019; 176: 557-568. DOI: 10.1007/s10549-018-05112-9
- 207 Lux MP, Emons J, Bani MR et al. Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. *Breast Care (Basel)* 2019; 14: 41-47. DOI: 10.1159/000495883
- 208 Fejzo MS, Fasching PA, Schneider MO et al. Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality. *Geburtshilfe Frauenheilkd* 2019; 79: 382-388. DOI: 10.1055/a-0830-1346
- 209 Ferreira MA, Gamazon ER, Al-Ejeh F et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun* 2019; 10: 1741. DOI: 10.1038/s41467-018-08053-5
- 210 Loibl S, Treue D, Budczies J et al. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. *Clin Cancer Res* 2019; 25: 3986-3995. DOI: 10.1158/1078-0432.CCR-18-3258
- 211 Nabieva N, Haberle L, Brucker SY et al. Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. *Int J Cancer* 2019; 145: 2114-2121. DOI: 10.1002/ijc.32294
- 212 Janni W, Schneeweiss A, Muller V et al. Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. *Geburtshilfe Frauenheilkd* 2019; 79: 268-280. DOI: 10.1055/a-0842-6661
- 213 Hartkopf AD, Muller V, Wockel A et al. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2019; 79: 256-267. DOI: 10.1055/a-0842-6614
- 214 Fasching PA, Gass P, Haberle L et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. *Breast Cancer Res Treat* 2019; 175: 617-625. DOI: 10.1007/s10549-019-05198-9
- 215 Escala-Garcia M, Guo Q, Dork T et al. Genome-wide association study of germline variants and breast cancer-specific mortality. *Br J Cancer* 2019; 120: 647-657. DOI: 10.1038/s41416-019-0393-x
- 216 Banys-Paluchowski M, Witzel I, Aktas B et al. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. *Sci Rep* 2019; 9: 2318. DOI: 10.1038/s41598-018-37259-2
- 217 Mayer IA, Prat A, Egle D et al. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). *Clin Cancer Res* 2019; 25: 2975-2987. DOI: 10.1158/1078-0432.CCR-18-3160
- 218 Janning M, Muller V, Vettorazzi E et al. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. *Int J Cancer* 2019; 145: 857-868. DOI: 10.1002/ijc.32163
- 219 Deniz M, DeGregorio A, DeGregorio N et al. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. *Breast* 2019; 44: 81-89. DOI: 10.1016/j.breast.2018.12.008
- 220 Lenz B, Eichler A, Schwenke E et al. Mindfulness-based Stress Reduction in Pregnancy: an App-Based Programme to Improve the Health of Mothers and Children (MINDFUL/PMI Study). *Geburtshilfe Frauenheilkd* 2018; 78: 1283-1291. DOI: 10.1055/a-0677-2630
- 221 Jiang X, Finucane HK, Schumacher FR et al. Shared heritability and functional enrichment across six solid cancers. *Nat Commun* 2019; 10: 431. DOI: 10.1038/s41467-018-08054-4
- 222 Poehls UG, Hack CC, Wunderle M et al. Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. *Eur J Cancer Prev* 2019; 28: 515-521. DOI: 10.1097/CEJ.0000000000000500
- 223 Matthies LM, Taran FA, Keilmann L et al. An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study. *J Med Internet Res* 2019; 21: e10004. DOI: 10.2196/10004

- 224 Wunderle M, Pretscher J, Brucker SY et al. Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. *Breast Cancer Res Treat* 2019; 174: 453-461. DOI: 10.1007/s10549-018-05115-6
- 225 Lux MP, Nabieva N, Hartkopf AD et al. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. *Cancers (Basel)* 2018; 11. DOI: 10.3390/cancers11010010
- 226 Konecny GE, Fasching PA. Editorial: The potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignancies. *Curr Opin Obstet Gynecol* 2019; 31: 1-3. DOI: 10.1097/GCO.0000000000000509
- 227 Schmid R, Wolf K, Robering JW et al. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. *BMC Cancer* 2018; 18: 1273. DOI: 10.1186/s12885-018-5166-z
- 228 Turner NC, Telli ML, Rugo HS et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Non-platinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). *Clin Cancer Res* 2019; 25: 2717-2724. DOI: 10.1158/1078-0432.CCR-18-1891
- 229 Yang Y, Wu L, Shu X et al. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Res* 2019; 79: 505-517. DOI: 10.1158/0008-5472.CAN-18-2726
- 230 Mavaddat N, Michailidou K, Dennis J et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet* 2019; 104: 21-34. DOI: 10.1016/j.ajhg.2018.11.002
- 231 Schneeweiss A, Mobus V, Tesch H et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. *Eur J Cancer* 2019; 106: 181-192. DOI: 10.1016/j.ejca.2018.10.015
- 232 Fasching PA, Schneeweiss A, Kolberg HC et al. Translational highlights in breast cancer research and treatment: recent developments with clinical impact. *Curr Opin Obstet Gynecol* 2019; 31: 67-75. DOI: 10.1097/GCO.0000000000000510
- 233 von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N Engl J Med* 2019; 380: 617-628. DOI: 10.1056/NEJMoa1814017
- 234 Hadji P, Stoetzer O, Decker T et al. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. *J Bone Oncol* 2019; 14: 010-010. DOI: 10.1016/j.jbo.2018.09.010
- 235 Hack CC, Antoniadis S, Beckmann MW et al. Supportive Infusions in Integrative Breast and Gynecological Oncology - Report on Patients' Satisfaction and Self-reported Effects and Side Effects. *Geburtshilfe Frauenheilkd* 2018; 78: 1129-1137. DOI: 10.1055/a-0754-2923
- 236 Muller V, Wockel A, Lux MP et al. Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2018; 78: 1119-1128. DOI: 10.1055/a-0715-2899
- 237 Wockel A, Lux MP, Janni W et al. Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2018; 78: 1110-1118. DOI: 10.1055/a-0715-2821
- 238 Erber R, Hartmann A, Beckmann MW et al. [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]. *Pathologe* 2018; 39: 236-240. DOI: 10.1007/s00292-018-0526-7
- 239 Gass P, Lux MP, Rauh C et al. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. *BMC Cancer* 2018; 18: 1051. DOI: 10.1186/s12885-018-4925-1
- 240 Wockel A, Festl J, Stuber T et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/0450L, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. *Geburtshilfe Frauenheilkd* 2018; 78: 927-948. DOI: 10.1055/a-0646-4522

- 241 Hurvitz SA, Quek RGW, Turner NC et al. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. *Eur J Cancer* 2018; 104: 160-168. DOI: 10.1016/j.ejca.2018.09.003
- 242 Loibl S, Weber KE, Timms KM et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. *Ann Oncol* 2018; 29: 2341-2347. DOI: 10.1093/annonc/mdy460
- 243 Fasching PA, Hartkopf AD, Gass P et al. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. *Breast Cancer Res Treat* 2019; 173: 319-328. DOI: 10.1007/s10549-018-5008-3
- 244 Trapp E, Janni W, Schindlbeck C et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. *J Natl Cancer Inst* 2019; 111: 380-387. DOI: 10.1093/jnci/djy152
- 245 Stevic I, Muller V, Weber K et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. *BMC Med* 2018; 16: 179. DOI: 10.1186/s12916-018-1163-y
- 246 Hoyer J, Vasileiou G, Uebe S et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. *BMC Cancer* 2018; 18: 926. DOI: 10.1186/s12885-018-4821-8
- 247 Schwenke E, Fasching PA, Faschingbauer F et al. Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. *Arch Gynecol Obstet* 2018; 298: 889-895. DOI: 10.1007/s00404-018-4888-0
- 248 Kelemen LE, Earp M, Fridley BL et al. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *Int J Mol Sci* 2018; 19. DOI: 10.3390/ijms19092473
- 249 Wachter DL, Wachter PW, Fasching PA et al. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. *Arch Pathol Lab Med* 2019; 143: 206-211. DOI: 10.5858/arpa.2017-0578-OA
- 250 Shimelis H, LaDuca H, Hu C et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. *J Natl Cancer Inst* 2018; 110: 855-862. DOI: 10.1093/jnci/djy106
- 251 Witzel I, Laakmann E, Weide R et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. *Eur J Cancer* 2018; 102: 1-9. DOI: 10.1016/j.ejca.2018.07.004
- 252 O'Mara TA, Glubb DM, Amant F et al. Identification of nine new susceptibility loci for endometrial cancer. *Nat Commun* 2018; 9: 3166. DOI: 10.1038/s41467-018-05427-7
- 253 Kahraman M, Roske A, Laufer T et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. *Sci Rep* 2018; 8: 11584. DOI: 10.1038/s41598-018-29917-2
- 254 Rambau PF, Vierkant RA, Intermaggio MP et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *J Pathol Clin Res* 2018; 4: 250-261. DOI: 10.1002/cjp2.109
- 255 Gass P, Untch M, Muller V et al. Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. *Geburtshilfe Frauenheilkd* 2018; 78: 707-714. DOI: 10.1055/a-0642-9462
- 256 Lu Y, Beeghly-Fadiel A, Wu L et al. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Res* 2018; 78: 5419-5430. DOI: 10.1158/0008-5472.CAN-18-0951
- 257 Hepp P, Fasching PA, Beckmann MW et al. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. *Clin Breast Cancer* 2018; 18: e1103-e1110. DOI: 10.1016/j.clbc.2018.06.006

- 258 Banys-Paluchowski M, Witzel I, Riethdorf S et al. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. *Breast Cancer Res Treat* 2018; 172: 93-104. DOI: 10.1007/s10549-018-4882-z
- 259 Frey S, Eichler A, Stonawski V et al. Prenatal Alcohol Exposure Is Associated With Adverse Cognitive Effects and Distinct Whole-Genome DNA Methylation Patterns in Primary School Children. *Front Behav Neurosci* 2018; 12: 125. DOI: 10.3389/fnbeh.2018.00125
- 260 Tesch H, Stoetzer O, Decker T et al. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. *Int J Cancer* 2019; 144: 877-885. DOI: 10.1002/ijc.31738
- 261 Gebrekidan MT, Erber R, Hartmann A et al. Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS). *Technol Cancer Res Treat* 2018; 17: 1533033818782532. DOI: 10.1177/1533033818782532
- 262 Earp M, Tyrer JP, Winham SJ et al. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS One* 2018; 13: e0197561. DOI: 10.1371/journal.pone.0197561
- 263 Brennan M, Gass P, Haberle L et al. The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. *Breast Cancer Res Treat* 2018; 171: 747-758. DOI: 10.1007/s10549-018-4829-4
- 264 Wurfel F, Erber R, Huebner H et al. TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. *Breast Care (Basel)* 2018; 13: 8-14. DOI: 10.1159/000486949
- 265 Bauer ECA, Schochter F, Widschwendter P et al. Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. *Breast Cancer Res Treat* 2018; 171: 571-580. DOI: 10.1007/s10549-018-4856-1
- 266 Wu L, Shi W, Long J et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet* 2018; 50: 968-978. DOI: 10.1038/s41588-018-0132-x
- 267 Ignatiadis M, Litiere S, Rothe F et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. *Ann Oncol* 2018; 29: 1777-1783. DOI: 10.1093/annonc/mdy211
- 268 Schulz-Wendtland R, Preuss C, Fasching PA et al. Galactography with Tomosynthesis Technique (Galactomosynthesis) - Renaissance of a Method? *Geburtshilfe Frauenheilkd* 2018; 78: 493-498. DOI: 10.1055/a-0594-2277
- 269 Wunderle M, Olmes G, Nabieva N et al. Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. *Geburtshilfe Frauenheilkd* 2018; 78: 481-492. DOI: 10.1055/a-0603-4350
- 270 Slamon DJ, Neven P, Chia S et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol* 2018; 36: 2465-2472. DOI: 10.1200/JCO.2018.78.9909
- 271 Hack CC, Hackl J, Huttner NBM et al. Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. *Integr Cancer Ther* 2018; 17: 941-951. DOI: 10.1177/1534735418777883
- 272 Fasching PA, Loibl S, Hu C et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *J Clin Oncol* 2018; 36: 2281-2287. DOI: 10.1200/JCO.2017.77.2285
- 273 Hack CC, Antoniadis S, Hackl J et al. Correction to: Breast cancer patients' satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. *Arch Gynecol Obstet* 2018; 298: 157-158. DOI: 10.1007/s00404-018-4785-6

- 274 Ingle JN, Kalari KR, Wickerham DL et al. Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. *Pharmacogenet Genomics* 2018; 28: 147-152. DOI: 10.1097/FPC.0000000000000337
- 275 Banys-Paluchowski M, Fehm T, Janni W et al. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. *BMC Cancer* 2018; 18: 541. DOI: 10.1186/s12885-018-4282-0
- 276 Wunderle M, Gass P, Haberle L et al. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. *Breast Cancer Res Treat* 2018; 171: 85-94. DOI: 10.1007/s10549-018-4797-8
- 277 Hack CC, Antoniadis S, Hackl J et al. Breast cancer patients' satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. *Arch Gynecol Obstet* 2018; 298: 147-156. DOI: 10.1007/s00404-018-4779-4
- 278 Poehls UG, Hack CC, Ekici AB et al. Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics. *Eur J Med Res* 2018; 23: 20. DOI: 10.1186/s40001-018-0318-9
- 279 Nabieva N, Fehm T, Haberle L et al. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. *Eur J Cancer* 2018; 96: 82-90. DOI: 10.1016/j.ejca.2018.03.020
- 280 Ghousaini M, Edwards SL, Michailidou K et al. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nat Commun* 2018; 9: 16193. DOI: 10.1038/ncomms16193
- 281 von Waldenfels G, Loibl S, Furlanetto J et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. *Oncotarget* 2018; 9: 15168-15179. DOI: 10.18632/oncotarget.24586
- 282 Painter JN, O'Mara TA, Morris AP et al. Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. *Cancer Med* 2018; 7: 1978-1987. DOI: 10.1002/cam4.1445
- 283 Stonawski V, Frey S, Golub Y et al. Associations of prenatal depressive symptoms with DNA methylation of HPA axis-related genes and diurnal cortisol profiles in primary school-aged children. *Dev Psychopathol* 2019; 31: 419-431. DOI: 10.1017/S0954579418000056
- 284 Mutschler NS, Scholz C, Friedl TWP et al. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. *Clin Breast Cancer* 2018; 18: 175-183. DOI: 10.1016/j.clbc.2018.01.008
- 285 Bidadi B, Liu D, Kalari KR et al. Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. *Front Pharmacol* 2018; 9: 158. DOI: 10.3389/fphar.2018.00158
- 286 Schneeweiss A, Lux MP, Janni W et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. *Geburtshilfe Frauenheilkd* 2018; 78: 246-259. DOI: 10.1055/s-0044-101614
- 287 Taran FA, Schneeweiss A, Lux MP et al. Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. *Geburtshilfe Frauenheilkd* 2018; 78: 237-245. DOI: 10.1055/s-0044-101613
- 288 Dixon-Suen SC, Nagle CM, Thrift AP et al. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *Br J Cancer* 2018; 118: 1123-1129. DOI: 10.1038/s41416-018-0011-3
- 289 Untch M, von Minckwitz G, Gerber B et al. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). *J Clin Oncol* 2018; 36: 1308-1316. DOI: 10.1200/JCO.2017.75.9175
- 290 Block MS, Vierkant RA, Rambau PF et al. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clin Proc* 2018; 93: 307-320. DOI: 10.1016/j.mayocp.2017.10.023
- 291 Emons J, Wunderle M, Hartmann A et al. Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. *Acta Radiol* 2018; 59: 1406-1413. DOI: 10.1177/0284185118762249

- 292 Schochter F, Rack B, Tzschaschel M et al. Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. *Oncol Res Treat* 2018; 41: 93-98. DOI: 10.1159/000485566
- 293 Eichler A, Heinrich H, Moll GH et al. Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. *Early Hum Dev* 2018; 119: 1-7. DOI: 10.1016/j.earlhumdev.2018.02.012
- 294 Huebner H, Fasching PA, Gumbrecht W et al. Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. *BMC Cancer* 2018; 18: 204. DOI: 10.1186/s12885-018-4115-1
- 295 Colombo M, Lopez-Perolio I, Meeks HD et al. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Hum Mutat* 2018; 39: 729-741. DOI: 10.1002/humu.23411
- 296 Alunni-Fabbroni M, Majunke L, Trapp EK et al. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. *BMC Cancer* 2018; 18: 141. DOI: 10.1186/s12885-018-4020-7
- 297 Fasching PA. Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? *Lancet Oncol* 2018; 19: 150-151. DOI: 10.1016/S1470-2045(18)30008-1
- 298 Rudolph A, Song M, Brook MN et al. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. *Int J Epidemiol* 2018; 47: 526-536. DOI: 10.1093/ije/dyx242
- 299 Polasik A, Tzschaschel M, Schochter F et al. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? *Geburtshilfe Frauenheilkd* 2017; 77: 1291-1298. DOI: 10.1055/s-0043-122884
- 300 Lux MP, Janni W, Hartkopf AD et al. Update Breast Cancer 2017 - Implementation of Novel Therapies. *Geburtshilfe Frauenheilkd* 2017; 77: 1281-1290. DOI: 10.1055/s-0043-122885
- 301 Jiao X, Aravidis C, Marikkannu R et al. PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget* 2017; 8: 102769-102782. DOI: 10.18632/oncotarget.21800
- 302 Muller V, Nabieva N, Haberle L et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. *Breast* 2018; 37: 154-160. DOI: 10.1016/j.breast.2017.08.008
- 303 Denkert C, von Minckwitz G, Darb-Esfahani S et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* 2018; 19: 40-50. DOI: 10.1016/S1470-2045(17)30904-X
- 304 Guo Q, Burgess S, Turman C et al. Body mass index and breast cancer survival: a Mendelian randomization analysis. *Int J Epidemiol* 2017; 46: 1814-1822. DOI: 10.1093/ije/dyx131
- 305 Banys-Paluchowski M, Witzel I, Riethdorf S et al. Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. *Sci Rep* 2017; 7: 17307. DOI: 10.1038/s41598-017-17514-8
- 306 Kadalayil L, Khan S, Nevanlinna H et al. Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. *Nat Commun* 2017; 8: 1632. DOI: 10.1038/s41467-017-01775-y
- 307 Brouckaert O, Rudolph A, Laenen A et al. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. *Breast Cancer Res* 2017; 19: 119. DOI: 10.1186/s13058-017-0909-3
- 308 Fasching PA, Haberle L, Rack B et al. Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. *Oncotarget* 2017; 8: 78133-78143. DOI: 10.18632/oncotarget.17726
- 309 Hartkopf AD, Huober J, Volz B et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. *Breast* 2018; 37: 42-51. DOI: 10.1016/j.breast.2017.10.002
- 310 De Gregorio A, Friedl TWP, Huober J et al. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. *JCO Precis Oncol* 2017; 1: 1-12. DOI: 10.1200/PO.17.00023

- 311 Michailidou K, Lindstrom S, Dennis J et al. Association analysis identifies 65 new breast cancer risk loci. *Nature* 2017; 551: 92-94. DOI: 10.1038/nature24284
- 312 Milne RL, Kuchenbaecker KB, Michailidou K et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet* 2017; 49: 1767-1778. DOI: 10.1038/ng.3785
- 313 Ovarian Tumor Tissue Analysis C, Goode EL, Block MS et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncol* 2017; 3: e173290. DOI: 10.1001/jamaoncol.2017.3290
- 314 Nabieva N, Kellner S, Fehm T et al. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. *Ann Oncol* 2018; 29: 186-192. DOI: 10.1093/annonc/mdx630
- 315 Glubb DM, Johnatty SE, Quinn MCJ et al. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget* 2017; 8: 64670-64684. DOI: 10.18632/oncotarget.18501
- 316 Wallwiener M, Matthies L, Simoes E et al. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. *J Med Internet Res* 2017; 19: e322. DOI: 10.2196/jmir.8210
- 317 Eichler A, Hudler L, Grunitz J et al. Effects of prenatal alcohol consumption on cognitive development and ADHD-related behaviour in primary-school age: a multilevel study based on meconium ethyl glucuronide. *J Child Psychol Psychiatry* 2018; 59: 110-118. DOI: 10.1111/jcpp.12794
- 318 van Mackelenbergh MT, Denkert C, Nekljudova V et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. *Breast Cancer Res Treat* 2018; 167: 59-71. DOI: 10.1007/s10549-017-4480-5
- 319 Minlikeeva AN, Freudenheim JL, Eng KH et al. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 2017; 26: 1470-1473. DOI: 10.1158/1055-9965.EPI-17-0367
- 320 Haberle L, Hack CC, Heusinger K et al. Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. *Eur J Med Res* 2017; 22: 30. DOI: 10.1186/s40001-017-0270-0
- 321 Wallwiener M, Heindl F, Brucker SY et al. Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. *Geburtshilfe Frauenheilkd* 2017; 77: 870-878. DOI: 10.1055/s-0043-116223
- 322 Hack CC, Emons J, Jud SM et al. Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. *Breast Cancer Res Treat* 2017; 166: 701-708. DOI: 10.1007/s10549-017-4446-7
- 323 Hartkopf AD, Graf J, Simoes E et al. Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. *JMIR Cancer* 2017; 3: e11. DOI: 10.2196/cancer.6996
- 324 Heidkamp GF, Sander J, Lehmann CHK et al. Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. *Sci Immunol* 2016; 1. DOI: 10.1126/sciimmunol.aai7677
- 325 Untch M, Huober J, Jackisch C et al. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). *Geburtshilfe Frauenheilkd* 2017; 77: 633-644. DOI: 10.1055/s-0043-111601
- 326 Kummel S, Paepke S, Huober J et al. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). *Eur J Cancer* 2017; 84: 1-8. DOI: 10.1016/j.ejca.2017.06.037

- 327 Haberle L, Hein A, Rubner M et al. Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. *Geburtshilfe Frauenheilkd* 2017; 77: 667-678. DOI: 10.1055/s-0043-111602
- 328 Hein A, Rack B, Li L et al. Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. *Geburtshilfe Frauenheilkd* 2017; 77: 651-659. DOI: 10.1055/s-0042-113189
- 329 Trapp E, Steidl J, Rack B et al. Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. *Breast* 2017; 35: 130-135. DOI: 10.1016/j.breast.2017.07.007
- 330 Hahnen E, Lederer B, Hauke J et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. *JAMA Oncol* 2017; 3: 1378-1385. DOI: 10.1001/jamaoncol.2017.1007
- 331 Schulz-Wendtland R, Jud SM, Fasching PA et al. A Standard Mammography Unit - Standard 3D Ultrasound Probe Fusion Prototype: First Results. *Geburtshilfe Frauenheilkd* 2017; 77: 679-685. DOI: 10.1055/s-0043-107034
- 332 Barrdahl M, Rudolph A, Hopper JL et al. Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *Int J Cancer* 2017; 141: 1830-1840. DOI: 10.1002/ijc.30859
- 333 Heinrich H, Grunitz J, Stonawski V et al. Attention, cognitive control and motivation in ADHD: Linking event-related brain potentials and DNA methylation patterns in boys at early school age. *Sci Rep* 2017; 7: 3823. DOI: 10.1038/s41598-017-03326-3
- 334 Banys-Paluchowski M, Witzel I, Riethdorf S et al. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. *Anticancer Res* 2017; 37: 3117-3128. DOI: 10.21873/anticancerres.11669
- 335 Hack CC, Stoll MJ, Jud SM et al. Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. *Cancer Med* 2017; 6: 1473-1481. DOI: 10.1002/cam4.1066
- 336 Day FR, Thompson DJ, Helgason H et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat Genet* 2017; 49: 834-841. DOI: 10.1038/ng.3841
- 337 Seuss H, Dankerl P, Ihle M et al. Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics. *Rofo* 2017; 189: e1. DOI: 10.1055/s-0035-1567202
- 338 Lenz B, Muhle C, Braun B et al. Prenatal and adult androgen activities in alcohol dependence. *Acta Psychiatr Scand* 2017; 136: 96-107. DOI: 10.1111/acps.12725
- 339 Phelan CM, Kuchenbaecker KB, Tyrer JP et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 2017; 49: 680-691. DOI: 10.1038/ng.3826
- 340 Seuss H, Dankerl P, Ihle M et al. Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics. *Rofo* 2017; 189: 661-671. DOI: 10.1055/s-0043-102939
- 341 Fremd C, Hack CC, Schneeweiss A et al. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. *Arch Gynecol Obstet* 2017; 295: 1239-1245. DOI: 10.1007/s00404-017-4348-2
- 342 Schulz-Wendtland R, Dankerl P, Bani MR et al. Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy. *Geburtshilfe Frauenheilkd* 2017; 77: 169-175. DOI: 10.1055/s-0042-124191
- 343 Shimelis H, Mesman RLS, Von Nicolai C et al. BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. *Cancer Res* 2017; 77: 2789-2799. DOI: 10.1158/0008-5472.CAN-16-2568
- 344 Lux MP, Fasching PA, Schrauder MG et al. The PI3K Pathway: Background and Treatment Approaches. *Breast Care (Basel)* 2016; 11: 398-404. DOI: 10.1159/000453133
- 345 Burghaus S, Fasching PA, Haberle L et al. Genetic risk factors for ovarian cancer and their role for endometriosis risk. *Gynecol Oncol* 2017; 145: 142-147. DOI: 10.1016/j.ygyno.2017.02.022

- 346 Schramm A, Schochter F, Friedl TWP et al. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. *Clin Breast Cancer* 2017; 17: 279-285. DOI: 10.1016/j.clbc.2016.11.008
- 347 Fagerholm R, Khan S, Schmidt MK et al. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. *Oncotarget* 2017; 8: 18381-18398. DOI: 10.18632/oncotarget.15110
- 348 Higgins M, Curigliano G, Dieras V et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. *Breast Cancer Res Treat* 2017; 162: 479-488. DOI: 10.1007/s10549-017-4130-y
- 349 Kolberg HC, Loevey G, Akpolat-Basci L et al. Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer. *Rev Recent Clin Trials* 2017; 12: 93-100. DOI: 10.2174/1574887112666170201142458
- 350 Kar SP, Adler E, Tyrer J et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *Br J Cancer* 2017; 116: 524-535. DOI: 10.1038/bjc.2016.426
- 351 Bayer CM, Beckmann MW, Fasching PA. Updates on the role of receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand/osteoprotegerin pathway in breast cancer risk and treatment. *Curr Opin Obstet Gynecol* 2017; 29: 4-11. DOI: 10.1097/GCO.0000000000000333
- 352 Schulz-Wendtland R, Harz M, Meier-Meitingner M et al. Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). *J Surg Oncol* 2017; 115: 238-242. DOI: 10.1002/jso.24510
- 353 Gass P, Fasching PA, Fehm T et al. Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvALuate-TM Study. *Breast Care (Basel)* 2016; 11: 315-322. DOI: 10.1159/000452468
- 354 Fasching PA, Gass P, Hein A. Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. *Breast Care (Basel)* 2016; 11: 313-314. DOI: 10.1159/000452463
- 355 Permuth JB, Reid B, Earp M et al. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget* 2016; 7: 72381-72394. DOI: 10.18632/oncotarget.10546
- 356 Kolberg HC, Loevey G, Akpolat-Basci L et al. Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy. *Strahlenther Onkol* 2017; 193: 62-69. DOI: 10.1007/s00066-016-1072-y
- 357 Liu J, Loncar I, Collee JM et al. rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. *Sci Rep* 2016; 6: 36874. DOI: 10.1038/srep36874
- 358 Painter JN, O'Mara TA, Marquart L et al. Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. *Cancer Epidemiol Biomarkers Prev* 2016; 25: 1503-1510. DOI: 10.1158/1055-9965.EPI-16-0147
- 359 Ingold Heppner B, Untch M, Denkert C et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. *Clin Cancer Res* 2016; 22: 5747-5754. DOI: 10.1158/1078-0432.CCR-15-2338
- 360 Hamdi Y, Soucy P, Adoue V et al. Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget* 2016; 7: 80140-80163. DOI: 10.18632/oncotarget.12818
- 361 Wallwiener M, Simoes E, Sokolov AN et al. Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients. *Geburtshilfe Frauenheilkd* 2016; 76: 1065-1073. DOI: 10.1055/s-0042-113188
- 362 Muranen TA, Blomqvist C, Dork T et al. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. *Breast Cancer Res* 2016; 18: 98. DOI: 10.1186/s13058-016-0758-5

- 363 Muranen TA, Greco D, Blomqvist C et al. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genet Med* 2017; 19: 599-603. DOI: 10.1038/gim.2016.147
- 364 Sucheston-Campbell LE, Cannioto R, Clay AI et al. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiol Biomarkers Prev* 2017; 26: 420-424. DOI: 10.1158/1055-9965.EPI-16-0631
- 365 Ghousaini M, French JD, Michailidou K et al. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *Am J Hum Genet* 2016; 99: 903-911. DOI: 10.1016/j.ajhg.2016.07.017
- 366 Hack CC, Fasching PA, Fehm T et al. Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. *Integr Cancer Ther* 2017; 16: 165-175. DOI: 10.1177/1534735416668575
- 367 Kraus C, Hoyer J, Vasileiou G et al. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. *Int J Cancer* 2017; 140: 95-102. DOI: 10.1002/ijc.30428
- 368 Lawrenson K, Kar S, McCue K et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun* 2016; 7: 12675. DOI: 10.1038/ncomms12675
- 369 Darabi H, Beesley J, Droit A et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Sci Rep* 2016; 6: 32512. DOI: 10.1038/srep32512
- 370 Southey MC, Goldgar DE, Winqvist R et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet* 2016; 53: 800-811. DOI: 10.1136/jmedgenet-2016-103839
- 371 Ong JS, Cuellar-Partida G, Lu Y et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *Int J Epidemiol* 2016; 45: 1619-1630. DOI: 10.1093/ije/dyw207
- 372 Burghaus S, Fehm T, Fasching PA et al. The International Endometriosis Evaluation Program (IEEP Study) - A Systematic Study for Physicians, Researchers and Patients. *Geburtshilfe Frauenheilkd* 2016; 76: 875-881. DOI: 10.1055/s-0042-106895
- 373 Eichler A, Grunitz J, Grimm J et al. Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy. *Alcohol* 2016; 54: 39-44. DOI: 10.1016/j.alcohol.2016.07.002
- 374 Horne HN, Chung CC, Zhang H et al. Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS One* 2016; 11: e0160316. DOI: 10.1371/journal.pone.0160316
- 375 Guo Y, Warren Andersen S, Shu XO et al. Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Med* 2016; 13: e1002105. DOI: 10.1371/journal.pmed.1002105
- 376 Hampras SS, Sucheston-Campbell LE, Cannioto R et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget* 2016; 7: 69097-69110. DOI: 10.18632/oncotarget.10215
- 377 Beckmann MW, Sell C, Aydogdu M et al. [Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]. *Gesundheitswesen* 2016; 78: e52. DOI: 10.1055/s-0042-113351
- 378 Zeng C, Guo X, Long J et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Res* 2016; 18: 64. DOI: 10.1186/s13058-016-0718-0
- 379 Kar SP, Beesley J, Amin AI Olama A et al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discov* 2016; 6: 1052-1067. DOI: 10.1158/2159-8290.CD-15-1227
- 380 Wyszynski A, Hong CC, Lam K et al. An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Hum Mol Genet* 2016; 25: 3863-3876. DOI: 10.1093/hmg/ddw223

- 381 Dixon SC, Nagle CM, Thrift AP et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *Int J Epidemiol* 2016; 45: 884-895. DOI: 10.1093/ije/dyw158
- 382 Haberle L, Fasching PA, Brehm B et al. Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. *Int J Cancer* 2016; 139: 1967-1974. DOI: 10.1002/ijc.30261
- 383 Jueckstock J, Rack B, Friedl TW et al. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. *BMC Cancer* 2016; 16: 401. DOI: 10.1186/s12885-016-2454-3
- 384 Denkert C, Wienert S, Poterie A et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. *Mod Pathol* 2016; 29: 1155-1164. DOI: 10.1038/modpathol.2016.109
- 385 von Minckwitz G, Rezai M, Tesch H et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-on (NaTaN) study (GBG 36/ABCSG 29). *Eur J Cancer* 2016; 64: 12-21. DOI: 10.1016/j.ejca.2016.05.015
- 386 Hein A, Gass P, Walter CB et al. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. *Breast Cancer Res Treat* 2016; 158: 59-65. DOI: 10.1007/s10549-016-3850-8
- 387 Schmidt MK, Hogervorst F, van Hien R et al. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *J Clin Oncol* 2016; 34: 2750-2760. DOI: 10.1200/JCO.2016.66.5844
- 388 Gao Y, Jones A, Fasching PA et al. Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. *Clin Epigenetics* 2016; 8: 63. DOI: 10.1186/s13148-016-0231-4
- 389 Schroder L, Rack B, Sommer H et al. Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. *Geburtshilfe Frauenheilkd* 2016; 76: 542-550. DOI: 10.1055/s-0042-106209
- 390 Pelttari LM, Khan S, Vuorela M et al. RAD51B in Familial Breast Cancer. *PLoS One* 2016; 11: e0153788. DOI: 10.1371/journal.pone.0153788
- 391 Cheng TH, Thompson DJ, O'Mara TA et al. Five endometrial cancer risk loci identified through genome-wide association analysis. *Nat Genet* 2016; 48: 667-674. DOI: 10.1038/ng.3562
- 392 Couch FJ, Kuchenbaecker KB, Michailidou K et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nat Commun* 2016; 7: 11375. DOI: 10.1038/ncomms11375
- 393 Kimmel M, Clive M, Gispen F et al. Oxytocin receptor DNA methylation in postpartum depression. *Psychoneuroendocrinology* 2016; 69: 150-160. DOI: 10.1016/j.psyneuen.2016.04.008
- 394 Shi J, Zhang Y, Zheng W et al. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *Int J Cancer* 2016; 139: 1303-1317. DOI: 10.1002/ijc.30150
- 395 Cuellar-Partida G, Lu Y, Dixon SC et al. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Hum Genet* 2016; 135: 741-756. DOI: 10.1007/s00439-016-1663-9
- 396 Zhao Z, Wen W, Michailidou K et al. Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes Control* 2016; 27: 679-693. DOI: 10.1007/s10552-016-0741-6
- 397 Dunning AM, Michailidou K, Kuchenbaecker KB et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet* 2016; 48: 374-386. DOI: 10.1038/ng.3521
- 398 Easton DF, Lesueur F, Decker B et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *J Med Genet* 2016; 53: 298-309. DOI: 10.1136/jmedgenet-2015-103529
- 399 Petridis C, Brook MN, Shah V et al. Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Res* 2016; 18: 22. DOI: 10.1186/s13058-016-0675-7

- 400 Schulz-Wendtland R, Fasching PA, Bani MR et al. Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up. *Geburtshilfe Frauenheilkd* 2016; 76: 59-64. DOI: 10.1055/s-0041-110395
- 401 French JD, Johnatty SE, Lu Y et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget* 2016; 7: 6353-6368. DOI: 10.18632/oncotarget.7047
- 402 Teschendorff AE, Gao Y, Jones A et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. *Nat Commun* 2016; 7: 10478. DOI: 10.1038/ncomms10478
- 403 Jim HS, Lin HY, Tyrer JP et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *J Genet Genome Res* 2015; 2. DOI: 10.23937/2378-3648/1410017
- 404 Loibl S, Darb-Esfahani S, Huober J et al. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. *Clin Cancer Res* 2016; 22: 2675-2683. DOI: 10.1158/1078-0432.CCR-15-0965
- 405 Janni WJ, Rack B, Terstappen LW et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. *Clin Cancer Res* 2016; 22: 2583-2593. DOI: 10.1158/1078-0432.CCR-15-1603
- 406 Almstedt K, Fasching PA, Scharl A et al. Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. *Anticancer Res* 2016; 36: 419-425.
- 407 Bolton KL, Tyrer J, Song H et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet* 2016; 48: 101. DOI: 10.1038/ng0116-101b
- 408 Gao Y, Jones A, Fasching PA et al. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. *Clin Epigenetics* 2015; 7: 126. DOI: 10.1186/s13148-015-0159-0
- 409 Lei J, Rudolph A, Moysich KB et al. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Hum Genet* 2016; 135: 137-154. DOI: 10.1007/s00439-015-1616-8
- 410 Meeks HD, Song H, Michailidou K et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J Natl Cancer Inst* 2016; 108. DOI: 10.1093/jnci/djv315
- 411 Thompson DJ, O'Mara TA, Glubb DM et al. CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. *Endocr Relat Cancer* 2016; 23: 77-91. DOI: 10.1530/ERC-15-0386
- 412 Jackisch C, Harbeck N, Huober J et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. *Breast Care (Basel)* 2015; 10: 211-219. DOI: 10.1159/000433590
- 413 Osborne L, Clive M, Kimmel M et al. Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels. *Neuropsychopharmacology* 2016; 41: 1648-1658. DOI: 10.1038/npp.2015.333
- 414 Burghaus S, Haberle L, Schrauder MG et al. Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study. *BMC Cancer* 2015; 15: 751. DOI: 10.1186/s12885-015-1821-9
- 415 Lawrenson K, Iversen ES, Tyrer J et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis* 2015; 36: 1341-1353. DOI: 10.1093/carcin/bgv138
- 416 Day FR, Ruth KS, Thompson DJ et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet* 2015; 47: 1294-1303. DOI: 10.1038/ng.3412
- 417 Amankwah EK, Lin HY, Tyrer JP et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genet Epidemiol* 2015; 39: 689-697. DOI: 10.1002/gepi.21921
- 418 Lawrenson K, Li Q, Kar S et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nat Commun* 2015; 6: 8234. DOI: 10.1038/ncomms9234

- 419 Widschwendter P, Friedl TW, Schwentner L et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. *Breast Cancer Res* 2015; 17: 129. DOI: 10.1186/s13058-015-0639-3
- 420 Guo X, Long J, Zeng C et al. Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2015; 24: 1680-1691. DOI: 10.1158/1055-9965.EPI-15-0363
- 421 Lindstrom S, Thompson DJ, Paterson AD et al. Corrigendum: genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nat Commun* 2015; 6: 8358. DOI: 10.1038/ncomms9358
- 422 O'Mara TA, Glubb DM, Painter JN et al. Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. *Endocr Relat Cancer* 2015; 22: 851-861. DOI: 10.1530/ERC-15-0319
- 423 Jamshidi M, Fagerholm R, Khan S et al. SNP-SNP interaction analysis of NF-kappaB signaling pathway on breast cancer survival. *Oncotarget* 2015; 6: 37979-37994. DOI: 10.18632/oncotarget.4991
- 424 Zhang B, Shu XO, Delahanty RJ et al. Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *J Natl Cancer Inst* 2015; 107. DOI: 10.1093/jnci/djv219
- 425 Rudolph A, Fasching PA, Behrens S et al. A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. *Breast Cancer Res* 2015; 17: 110. DOI: 10.1186/s13058-015-0625-9
- 426 Lux MP, Hildebrandt T, Knetzger SM et al. Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. *BMC Cancer* 2015; 15: 587. DOI: 10.1186/s12885-015-1584-3
- 427 Beckmann M, Sell C, Aydogdu M et al. [Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]. *Gesundheitswesen* 2016; 78: 438-445. DOI: 10.1055/s-0035-1554707
- 428 Lu Y, Cuellar-Partida G, Painter JN et al. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Hum Mol Genet* 2015; 24: 5955-5964. DOI: 10.1093/hmg/ddv306
- 429 Kar SP, Tyrer JP, Li Q et al. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiol Biomarkers Prev* 2015; 24: 1574-1584. DOI: 10.1158/1055-9965.EPI-14-1270
- 430 Rauh C, Schuetz F, Rack B et al. Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. *Geburtshilfe Frauenheilkd* 2015; 75: 588-596. DOI: 10.1055/s-0035-1546149
- 431 Untch M, Harbeck N, Huober J et al. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). *Geburtshilfe Frauenheilkd* 2015; 75: 556-565. DOI: 10.1055/s-0035-1546120
- 432 Johnatty SE, Tyrer JP, Kar S et al. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clin Cancer Res* 2015; 21: 5264-5276. DOI: 10.1158/1078-0432.CCR-15-0632
- 433 Nagle CM, Dixon SC, Jensen A et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *Br J Cancer* 2015; 113: 817-826. DOI: 10.1038/bjc.2015.245
- 434 Hein A, Lambrechts D, von Minckwitz G et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III Gepar-Quinto study. *Int J Cancer* 2015; 137: 2981-2988. DOI: 10.1002/ijc.29656
- 435 Chornokur G, Lin HY, Tyrer JP et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS One* 2015; 10: e0128106. DOI: 10.1371/journal.pone.0128106

- 436 Darabi H, McCue K, Beesley J et al. Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *Am J Hum Genet* 2015; 97: 22-34. DOI: 10.1016/j.ajhg.2015.05.002
- 437 Hack CC, Huttner NB, Fasching PA et al. Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology. *Geburtshilfe Frauenheilkd* 2015; 75: 377-383. DOI: 10.1055/s-0035-1545850
- 438 Ovarian Cancer Association Consortium BCAC, Consortium of Modifiers of B, Brca et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol* 2016; 141: 386-401. DOI: 10.1016/j.ygyno.2015.04.034
- 439 Pirie A, Guo Q, Kraft P et al. Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Res* 2015; 17: 58. DOI: 10.1186/s13058-015-0570-7
- 440 Guo Q, Schmidt MK, Kraft P et al. Identification of novel genetic markers of breast cancer survival. *J Natl Cancer Inst* 2015; 107. DOI: 10.1093/jnci/djv081
- 441 Garczyk S, von Stillfried S, Antonopoulos W et al. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection. *PLoS One* 2015; 10: e0122106. DOI: 10.1371/journal.pone.0122106
- 442 Stone J, Thompson DJ, Dos Santos Silva I et al. Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. *Cancer Res* 2015; 75: 2457-2467. DOI: 10.1158/0008-5472.CAN-14-2012
- 443 Mavaddat N, Pharoah PD, Michailidou K et al. Prediction of breast cancer risk based on profiling with common genetic variants. *J Natl Cancer Inst* 2015; 107. DOI: 10.1093/jnci/djv036
- 444 Lei J, Rudolph A, Moysich KB et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. *Breast Cancer Res* 2015; 17: 18. DOI: 10.1186/s13058-015-0522-2
- 445 Fagerholm R, Schmidt MK, Khan S et al. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. *Oncotarget* 2015; 6: 7390-7407. DOI: 10.18632/oncotarget.3506
- 446 Maass N, Schutz F, Fasching PA et al. Breast Cancer Update 2014 - Focus on the Patient and the Tumour. *Geburtshilfe Frauenheilkd* 2015; 75: 170-182. DOI: 10.1055/s-0035-1545704
- 447 Renner SP, Strissel PL, Beckmann MW et al. Inhibition of adhesion, proliferation, and invasion of primary endometriosis and endometrial stromal and ovarian carcinoma cells by a nonhyaluronan adhesion barrier gel. *Biomed Res Int* 2015; 2015: 450468. DOI: 10.1155/2015/450468
- 448 Michailidou K, Beesley J, Lindstrom S et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet* 2015; 47: 373-380. DOI: 10.1038/ng.3242
- 449 Vachon CM, Pankratz VS, Scott CG et al. The contributions of breast density and common genetic variation to breast cancer risk. *J Natl Cancer Inst* 2015; 107. DOI: 10.1093/jnci/dju397
- 450 Schulz-Wendtland R, Dankerl P, Dilbat G et al. Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips. *Geburtshilfe Frauenheilkd* 2015; 75: 72-76. DOI: 10.1055/s-0034-1396164
- 451 Fasching PA, Brucker SY, Fehm TN et al. Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. *Geburtshilfe Frauenheilkd* 2015; 75: 41-50. DOI: 10.1055/s-0034-1396215
- 452 Orr N, Dudbridge F, Dryden N et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet* 2015; 24: 2966-2984. DOI: 10.1093/hmg/ddv035
- 453 Pearce CL, Stram DO, Ness RB et al. Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiol Biomarkers Prev* 2015; 24: 671-676. DOI: 10.1158/1055-9965.EPI-14-1128
- 454 Kabisch M, Lorenzo Bermejo J, Dunnebie T et al. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis* 2015; 36: 256-271. DOI: 10.1093/carcin/bgu326

- 455 Kuchenbaecker KB, Ramus SJ, Tyrer J et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet* 2015; 47: 164-171. DOI: 10.1038/ng.3185
- 456 Wang L, Bohler T, Zohrer F et al. A hybrid method towards automated nipple detection in 3D breast ultrasound images. *Annu Int Conf IEEE Eng Med Biol Soc* 2014; 2014: 2869-2872. DOI: 10.1109/EMBC.2014.6944222
- 457 Fasching PA, Fehm T, Kellner S et al. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. *Geburtshilfe Frauenheilkd* 2014; 74: 1137-1143. DOI: 10.1055/s-0034-1383401
- 458 Glubb DM, Maranian MJ, Michailidou K et al. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *Am J Hum Genet* 2015; 96: 5-20. DOI: 10.1016/j.ajhg.2014.11.009
- 459 Lee AW, Tyrer JP, Doherty JA et al. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecol Oncol* 2015; 136: 542-548. DOI: 10.1016/j.ygyno.2014.12.017
- 460 Rauh C, Gass P, Heusinger K et al. Association of molecular subtypes with breast cancer risk factors: a case-only analysis. *Eur J Cancer Prev* 2015; 24: 484-490. DOI: 10.1097/CEJ.000000000000111
- 461 Carvajal-Carmona LG, O'Mara TA, Painter JN et al. Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. *Hum Genet* 2015; 134: 231-245. DOI: 10.1007/s00439-014-1515-4
- 462 Couch FJ, Hart SN, Sharma P et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol* 2015; 33: 304-311. DOI: 10.1200/JCO.2014.57.1414
- 463 Khan S, Greco D, Michailidou K et al. MicroRNA related polymorphisms and breast cancer risk. *PLoS One* 2014; 9: e109973. DOI: 10.1371/journal.pone.0109973
- 464 Painter JN, O'Mara TA, Batra J et al. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Hum Mol Genet* 2015; 24: 1478-1492. DOI: 10.1093/hmg/ddu552
- 465 Polzer B, Medoro G, Pasch S et al. Molecular profiling of single circulating tumor cells with diagnostic intention. *EMBO Mol Med* 2014; 6: 1371-1386. DOI: 10.15252/emmm.201404033
- 466 Lindner JL, Loibl S, Denkert C et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. *Ann Oncol* 2015; 26: 95-100. DOI: 10.1093/annonc/mdu487
- 467 Kobel M, Madore J, Ramus SJ et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. *An Ovarian Tumour Tissue Analysis consortium study*. *Br J Cancer* 2014; 111: 2297-2307. DOI: 10.1038/bjc.2014.567
- 468 Lindstrom S, Thompson DJ, Paterson AD et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nat Commun* 2014; 5: 5303. DOI: 10.1038/ncomms6303
- 469 Kaeppler S, Bayer F, Weber T et al. Signal decomposition for X-ray dark-field imaging. *Med Image Comput Comput Assist Interv* 2014; 17: 170-177. DOI: 10.1007/978-3-319-10404-1_22
- 470 Salmen J, Neugebauer J, Fasching PA et al. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. *Breast Cancer Res Treat* 2014; 148: 143-151. DOI: 10.1007/s10549-014-3130-4
- 471 Ghousaini M, Edwards SL, Michailidou K et al. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nat Commun* 2014; 4: 4999. DOI: 10.1038/ncomms5999
- 472 Perry JR, Day F, Elks CE et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* 2014; 514: 92-97. DOI: 10.1038/nature13545
- 473 Rudolph A, Milne RL, Truong T et al. Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *Int J Cancer* 2015; 136: E685-696. DOI: 10.1002/ijc.29188

- 474 von Minckwitz G, Loibl S, Untch M et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger. *Ann Oncol* 2014; 25: 2363-2372. DOI: 10.1093/annonc/mdu455
- 475 Lux MP, Sell CS, Fasching PA et al. Time and Resources Needed to Document Patients with Breast Cancer from Primary Diagnosis to Follow-up - Results of a Single-center Study. *Geburtshilfe Frauenheilkd* 2014; 74: 743-751. DOI: 10.1055/s-0034-1382980
- 476 Loibl S, von Minckwitz G, Schneeweiss A et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol* 2014; 32: 3212-3220. DOI: 10.1200/JCO.2014.55.7876
- 477 Lin WY, Camp NJ, Ghossaini M et al. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Hum Mol Genet* 2015; 24: 285-298. DOI: 10.1093/hmg/ddu431
- 478 Fasching PA, Konecny GE, Spurdle AB. Biomarkers in women's cancers, gynecology, and obstetrics. *Biomed Res Int* 2014; 2014: 602340. DOI: 10.1155/2014/602340
- 479 Muller V, Gade S, Steinbach B et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. *Breast Cancer Res Treat* 2014; 147: 61-68. DOI: 10.1007/s10549-014-3079-3
- 480 Kelemen LE, Terry KL, Goodman MT et al. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Mol Nutr Food Res* 2014; 58: 2023-2035. DOI: 10.1002/mnfr.201400068
- 481 Shen J, Hu Q, Schrauder M et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. *Oncotarget* 2014; 5: 5284-5294. DOI: 10.18632/oncotarget.2014
- 482 Hein A, Fasching PA, Goecke TW. Response to "screening depression during and after pregnancy using the EPDS". *Arch Gynecol Obstet* 2014; 290: 603. DOI: 10.1007/s00404-014-3337-y
- 483 Milne RL, Burwinkel B, Michailidou K et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol Genet* 2014; 23: 6096-6111. DOI: 10.1093/hmg/ddu311
- 484 Li J, Lindstrom LS, Foo JN et al. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. *Nat Commun* 2014; 5: 4051. DOI: 10.1038/ncomms5051
- 485 Purrington KS, Slettedahl S, Bolla MK et al. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Hum Mol Genet* 2014; 23: 6034-6046. DOI: 10.1093/hmg/ddu300
- 486 Johnson N, Dudbridge F, Orr N et al. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Res* 2014; 16: R51. DOI: 10.1186/bcr3662
- 487 Rack B, Schindlbeck C, Juckstock J et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. *J Natl Cancer Inst* 2014; 106. DOI: 10.1093/jnci/dju066
- 488 Goecke TW, Burger P, Fasching PA et al. Meconium indicators of maternal alcohol abuse during pregnancy and association with patient characteristics. *Biomed Res Int* 2014; 2014: 702848. DOI: 10.1155/2014/702848
- 489 von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* 2014; 15: 747-756. DOI: 10.1016/S1470-2045(14)70160-3
- 490 Schulz-Wendtland R, Dilbat G, Bani M et al. Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy? *Geburtshilfe Frauenheilkd* 2013; 73: 422-427. DOI: 10.1055/s-0032-1328600

- 491 Fasching PA, Ekici AB, Wachter DL et al. Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis. *Geburtshilfe Frauenheilkd* 2013; 73: 1228-1235. DOI: 10.1055/s-0033-1360178
- 492 Schulz-Wendtland R, Dankerl P, Dilbat G et al. Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer. *Geburtshilfe Frauenheilkd* 2013; 73: 1135-1138. DOI: 10.1055/s-0033-1351086
- 493 Charbonneau B, Moysich KB, Kalli KR et al. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunol Res* 2014; 2: 332-340. DOI: 10.1158/2326-6066.CIR-13-0136
- 494 Sawyer E, Roylance R, Petridis C et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genet* 2014; 10: e1004285. DOI: 10.1371/journal.pgen.1004285
- 495 Schneider M, Engel A, Fasching PA et al. Genetic variants in the genes of the stress hormone signaling pathway and depressive symptoms during and after pregnancy. *Biomed Res Int* 2014; 2014: 469278. DOI: 10.1155/2014/469278
- 496 Block MS, Charbonneau B, Vierkant RA et al. Variation in NF-kappaB signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2014; 23: 1421-1427. DOI: 10.1158/1055-9965.EPI-13-0962
- 497 Hein A, Bayer CM, Schrauder MG et al. Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. *Biomed Res Int* 2014; 2014: 842452. DOI: 10.1155/2014/842452
- 498 Wachter DL, Hartmann A, Beckmann MW et al. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. *Biomed Res Int* 2014; 2014: 408459. DOI: 10.1155/2014/408459
- 499 Fasching PA, Weihbrecht S, Haeberle L et al. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. *Breast Cancer Res Treat* 2014; 145: 193-203. DOI: 10.1007/s10549-014-2922-x
- 500 Schulz-Wendtland R, Wittenberg T, Michel T et al. [Future of mammography-based imaging]. *Radio- loge* 2014; 54: 217-223. DOI: 10.1007/s00117-013-2578-2
- 501 Agarwal D, Pineda S, Michailidou K et al. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *Br J Cancer* 2014; 110: 1088-1100. DOI: 10.1038/bjc.2013.769
- 502 Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014; 384: 164-172. DOI: 10.1016/S0140-6736(13)62422-8
- 503 Hildebrandt T, Thiel FC, Fasching PA et al. Health utilities in gynecological oncology and mastology in Germany. *Anticancer Res* 2014; 34: 829-835.
- 504 Loibl S, Volz C, Mau C et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat* 2014; 144: 153-162. DOI: 10.1007/s10549-014-2861-6
- 505 Fasching PA, Jud SM, Hauschild M et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. *BMC Cancer* 2014; 14: 66. DOI: 10.1186/1471-2407-14-66
- 506 Jud SM, Hatko R, Maihofner C et al. Comprehensive visualization of paresthesia in breast cancer survivors. *Arch Gynecol Obstet* 2014; 290: 135-141. DOI: 10.1007/s00404-014-3164-1
- 507 Strehl JD, Hackl J, Wachter DL et al. Correlation of histological and macroscopic findings in peritoneal endometriosis. *Int J Clin Exp Pathol* 2014; 7: 152-162.
- 508 Wachter DL, Rauh C, Wenkel E et al. [Sebaceous breast carcinoma: report of a rare histological special subtype]. *Pathologe* 2014; 35: 72-76. DOI: 10.1007/s00292-013-1844-4
- 509 Spurdle AB, Couch FJ, Parsons MT et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Res* 2014; 16: 3419. DOI: 10.1186/s13058-014-0474-y

- 510 Perry JR, Hsu YH, Chasman DI et al. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Hum Mol Genet* 2014; 23: 2490-2497. DOI: 10.1093/hmg/ddt620
- 511 Adamietz BR, Fasching PA, Jud S et al. Ultrasound elastography of pulmonary lesions - a feasibility study. *Ultraschall Med* 2014; 35: 33-37. DOI: 10.1055/s-0033-1355893
- 512 Purrington KS, Slager S, Eccles D et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. *Carcinogenesis* 2014; 35: 1012-1019. DOI: 10.1093/carcin/bgt404
- 513 Lux MP, Kraml F, Wagner S et al. Financial viability of perinatal centers in the longer term, taking legislative requirements into account. An examination of the cost-revenue structure of a Level I perinatal center. *In Vivo* 2013; 27: 855-867.
- 514 Meyer KB, O'Reilly M, Michailidou K et al. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *Am J Hum Genet* 2013; 93: 1046-1060. DOI: 10.1016/j.ajhg.2013.10.026
- 515 von Minckwitz G, Rezai M, Fasching PA et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--Gepar-Quattro). *Ann Oncol* 2014; 25: 81-89. DOI: 10.1093/annonc/mdt410
- 516 Charbonneau B, Block MS, Bamlet WR et al. Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. *Cancer Res* 2014; 74: 852-861. DOI: 10.1158/0008-5472.CAN-13-1051
- 517 Schoeps A, Rudolph A, Seibold P et al. Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genet Epidemiol* 2014; 38: 84-93. DOI: 10.1002/gepi.21771
- 518 Milne RL, Herranz J, Michailidou K et al. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Hum Mol Genet* 2014; 23: 1934-1946. DOI: 10.1093/hmg/ddt581
- 519 Earp MA, Kelemen LE, Magliocco AM et al. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Hum Genet* 2014; 133: 481-497. DOI: 10.1007/s00439-013-1383-3
- 520 Gerber B, Loibl S, Eidtmann H et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). *Ann Oncol* 2013; 24: 2978-2984. DOI: 10.1093/annonc/mdt361
- 521 Hein A, Rauh C, Engel A et al. Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). *Arch Gynecol Obstet* 2014; 289: 755-763. DOI: 10.1007/s00404-013-3046-y
- 522 Bayer CM, Bani MR, Schneider M et al. Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. *Eur J Cancer Prev* 2014; 23: 151-157. DOI: 10.1097/CEJ.0b013e3283651ccb
- 523 Province MA, Goetz MP, Brauch H et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. *Clin Pharmacol Ther* 2014; 95: 216-227. DOI: 10.1038/clpt.2013.186
- 524 Johnatty SE, Beesley J, Gao B et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. *Gynecol Oncol* 2013; 131: 8-14. DOI: 10.1016/j.ygyno.2013.07.107
- 525 Crown JP, Dieras V, Staroslawska E et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. *J Clin Oncol* 2013; 31: 2870-2878. DOI: 10.1200/JCO.2012.43.3391
- 526 Saura C, Tseng LM, Chan S et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of betaIII-tubulin expression as a predictive marker. *Oncologist* 2013; 18: 787-794. DOI: 10.1634/theoncologist.2013-0075
- 527 Justenhoven C, Pentimalli D, Rabstein S et al. CYP2B6*6 is associated with increased breast cancer risk. *Int J Cancer* 2014; 134: 426-430. DOI: 10.1002/ijc.28356

- 528 von Minckwitz G, Schmitt WD, Loibl S et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. *Clin Cancer Res* 2013; 19: 4521-4531. DOI: 10.1158/1078-0432.CCR-12-3628
- 529 Justenhoven C, Obazee O, Winter S et al. The UGT1A6_19_GG genotype is a breast cancer risk factor. *Front Genet* 2013; 4: 104. DOI: 10.3389/fgene.2013.00104
- 530 Lux MP, Bayer CM, Loehberg CR et al. Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. *Breast Cancer Res Treat* 2013; 139: 429-440. DOI: 10.1007/s10549-013-2557-3
- 531 Michel T, Rieger J, Anton G et al. On a dark-field signal generated by micrometer-sized calcifications in phase-contrast mammography. *Phys Med Biol* 2013; 58: 2713-2732. DOI: 10.1088/0031-9155/58/8/2713
- 532 Nickels S, Truong T, Hein R et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genet* 2013; 9: e1003284. DOI: 10.1371/journal.pgen.1003284
- 533 Gaudet MM, Kuchenbaecker KB, Vijai J et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genet* 2013; 9: e1003173. DOI: 10.1371/journal.pgen.1003173
- 534 Huober J, Fasching PA, Hanusch C et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/- bevacizumab - results of the randomised GeparQuinto study (GBG 44). *Eur J Cancer* 2013; 49: 2284-2293. DOI: 10.1016/j.ejca.2013.02.027
- 535 French JD, Ghousaini M, Edwards SL et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet* 2013; 92: 489-503. DOI: 10.1016/j.ajhg.2013.01.002
- 536 Garcia-Closas M, Couch FJ, Lindstrom S et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet* 2013; 45: 392-398, 398e391-392. DOI: 10.1038/ng.2561
- 537 Bojesen SE, Pooley KA, Johnatty SE et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet* 2013; 45: 371-384, 384e371-372. DOI: 10.1038/ng.2566
- 538 Pharoah PD, Tsai YY, Ramus SJ et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* 2013; 45: 362-370, 370e361-362. DOI: 10.1038/ng.2564
- 539 Michailidou K, Hall P, Gonzalez-Neira A et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet* 2013; 45: 353-361, 361e351-352. DOI: 10.1038/ng.2563
- 540 Shen H, Fridley BL, Song H et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun* 2013; 4: 1628. DOI: 10.1038/ncomms2629
- 541 Permut-Wey J, Lawrenson K, Shen HC et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun* 2013; 4: 1627. DOI: 10.1038/ncomms2613
- 542 White KL, Vierkant RA, Fogarty ZC et al. Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 987-992. DOI: 10.1158/1055-9965.EPI-13-0028
- 543 Loehberg CR, Almstedt K, Jud SM et al. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. *Breast Cancer Res Treat* 2013; 138: 899-908. DOI: 10.1007/s10549-013-2460-y
- 544 Denkert C, Huober J, Loibl S et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. *Breast Cancer Res* 2013; 15: R11. DOI: 10.1186/bcr3384
- 545 Anton G, Bayer F, Beckmann MW et al. Grating-based darkfield imaging of human breast tissue. *Z Med Phys* 2013; 23: 228-235. DOI: 10.1016/j.zemedi.2013.01.001

- 546 Hack CC, Haberle L, Geisler K et al. Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients. *Geburtshilfe Frauenheilkd* 2013; 73: 136-141. DOI: 10.1055/s-0032-1328291
- 547 Kloten V, Becker B, Winner K et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. *Breast Cancer Res* 2013; 15: R4. DOI: 10.1186/bcr3375
- 548 Serce NB, Boesl A, Klamann I et al. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. *BMC Cancer* 2012; 12: 597. DOI: 10.1186/1471-2407-12-597
- 549 Delahanty RJ, Xiang YB, Spurdle A et al. Polymorphisms in inflammation pathway genes and endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 216-223. DOI: 10.1158/1055-9965.EPI-12-0903
- 550 Stockmann P, Nkenke E, Englbrecht M et al. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. *J Craniomaxillofac Surg* 2013; 41: 71-75. DOI: 10.1016/j.jcms.2012.10.018
- 551 Luftner D, Lux MP, Maass N et al. Advances in Breast Cancer - Looking Back over the Year. *Geburtshilfe Frauenheilkd* 2012; 72: 1117-1129. DOI: 10.1055/s-0032-1328084
- 552 Weischer M, Nordestgaard BG, Pharoah P et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *J Clin Oncol* 2012; 30: 4308-4316. DOI: 10.1200/JCO.2012.42.7336
- 553 Thiel FC, Scharl A, Hildebrandt T et al. Financing of certified centers: a willingness-to-pay analysis. *Arch Gynecol Obstet* 2013; 287: 495-509. DOI: 10.1007/s00404-012-2572-3
- 554 Rauh C, Faschingbauer F, Haeberle L et al. Factors influencing breast changes after pregnancy. *Eur J Cancer Prev* 2013; 22: 259-261. DOI: 10.1097/CEJ.0b013e328359cb81
- 555 Siddiq A, Couch FJ, Chen GK et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Hum Mol Genet* 2012; 21: 5373-5384. DOI: 10.1093/hmg/dds381
- 556 Wachter DL, Fasching PA, Haeberle L et al. Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. *Arch Gynecol Obstet* 2013; 287: 337-344. DOI: 10.1007/s00404-012-2534-9
- 557 Heusinger K, Jud SM, Haberle L et al. Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. *Breast Cancer Res Treat* 2012; 135: 885-892. DOI: 10.1007/s10549-012-2221-3
- 558 Schmidt M, Fasching PA, Beckmann MW et al. Biomarkers in Breast Cancer - An Update. *Geburtshilfe Frauenheilkd* 2012; 72: 819-832. DOI: 10.1055/s-0032-1315340
- 559 Thiel FC, Schrauder MG, Fasching PA et al. Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. *Breast Cancer Res Treat* 2012; 135: 811-820. DOI: 10.1007/s10549-012-2218-y
- 560 Muller V, Riethdorf S, Rack B et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. *Breast Cancer Res* 2012; 14: R118. DOI: 10.1186/bcr3243
- 561 Witzel I, Loibl S, von Minckwitz G et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. *Br J Cancer* 2012; 107: 956-960. DOI: 10.1038/bjc.2012.353
- 562 Hein R, Maranian M, Hopper JL et al. Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS One* 2012; 7: e42380. DOI: 10.1371/journal.pone.0042380
- 563 Sohler F, Sommer A, Wachter DL et al. Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesions. *Reprod Sci* 2013; 20: 85-102. DOI: 10.1177/1933719112451147
- 564 Warren H, Dudbridge F, Fletcher O et al. 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 2012; 21: 1783-1791. DOI: 10.1158/1055-9965.EPI-12-0526

- 565 Wishart GC, Bajdik CD, Dicks E et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *Br J Cancer* 2012; 107: 800-807. DOI: 10.1038/bjc.2012.338
- 566 Rauh C, Beetz A, Burger P et al. Delivery mode and the course of pre- and postpartum depression. *Arch Gynecol Obstet* 2012; 286: 1407-1412. DOI: 10.1007/s00404-012-2470-8
- 567 Rauh C, Hack CC, Haberle L et al. Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer. *Geburtshilfe Frauenheilkd* 2012; 72: 727-733. DOI: 10.1055/s-0032-1315129
- 568 Schuler M, Awada A, Harter P et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. *Breast Cancer Res Treat* 2012; 134: 1149-1159. DOI: 10.1007/s10549-012-2126-1
- 569 Kolberg HC, Luftner D, Lux MP et al. Breast Cancer 2012 - New Aspects. *Geburtshilfe Frauenheilkd* 2012; 72: 602-615. DOI: 10.1055/s-0032-1315131
- 570 Fasching PA, Faschingbauer F, Goecke TW et al. Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. *J Psychiatr Res* 2012; 46: 1109-1117. DOI: 10.1016/j.jpsychires.2012.05.011
- 571 Hein A, Thiel FC, Bayer CM et al. Hormone replacement therapy and prognosis in ovarian cancer patients. *Eur J Cancer Prev* 2013; 22: 52-58. DOI: 10.1097/CEJ.0b013e328355ec22
- 572 Schulz-Wendtland R, Dilbat G, Bani M et al. Full Field Digital Mammography (FFDM) versus CMOS Technology versus Tomosynthesis (DBT) - Which System Increases the Quality of Intraoperative Imaging? *Geburtshilfe Frauenheilkd* 2012; 72: 532-538. DOI: 10.1055/s-0032-1314942
- 573 Lux MP, Reichelt C, Karnon J et al. Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System. *Breast Care (Basel)* 2011; 6: 381-389. DOI: 10.1159/000333118
- 574 Renner SP, Boosz AS, Burghaus S et al. Visual pain mapping in endometriosis. *Arch Gynecol Obstet* 2012; 286: 687-693. DOI: 10.1007/s00404-012-2369-4
- 575 Schulz-Wendtland R, Bani M, Lux MP et al. Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se. *Geburtshilfe Frauenheilkd* 2012; 72: 408-411. DOI: 10.1055/s-0031-1298158
- 576 Fasching PA, Pharoah PD, Cox A et al. The role of genetic breast cancer susceptibility variants as prognostic factors. *Hum Mol Genet* 2012; 21: 3926-3939. DOI: 10.1093/hmg/dds159
- 577 von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30: 1796-1804. DOI: 10.1200/JCO.2011.38.8595
- 578 Haberle L, Wagner F, Fasching PA et al. Characterizing mammographic images by using generic texture features. *Breast Cancer Res* 2012; 14: R59. DOI: 10.1186/bcr3163
- 579 Lambrechts D, Truong T, Justenhoven C et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. *Hum Mutat* 2012; 33: 1123-1132. DOI: 10.1002/humu.22089
- 580 Vachon CM, Scott CG, Fasching PA et al. Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2012; 21: 1156-1166. DOI: 10.1158/1055-9965.EPI-12-0066
- 581 Long J, Zheng W, Xiang YB et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. *Cancer Epidemiol Biomarkers Prev* 2012; 21: 980-987. DOI: 10.1158/1055-9965.EPI-11-1160
- 582 Heusinger K, Jud SM, Haberle L et al. Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study. *Int J Cancer* 2012; 131: 2643-2649. DOI: 10.1002/ijc.27515
- 583 Pearce CL, Templeman C, Rossing MA et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 2012; 13: 385-394. DOI: 10.1016/S1470-2045(11)70404-1

- 584 Stevens KN, Fredericksen Z, Vachon CM et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Res* 2012; 72: 1795-1803. DOI: 10.1158/0008-5472.CAN-11-3364
- 585 von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012; 366: 299-309. DOI: 10.1056/NEJMoa1111065
- 586 Ghossaini M, Fletcher O, Michailidou K et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nat Genet* 2012; 44: 312-318. DOI: 10.1038/ng.1049
- 587 Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol* 2012; 13: 135-144. DOI: 10.1016/S1470-2045(11)70397-7
- 588 Schrauder MG, Strick R, Schulz-Wendtland R et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. *PLoS One* 2012; 7: e29770. DOI: 10.1371/journal.pone.0029770
- 589 Mehta D, Quast C, Fasching PA et al. The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms. *J Affect Disord* 2012; 136: 1192-1197. DOI: 10.1016/j.jad.2011.11.042
- 590 Adamietz BR, Kahmann L, Fasching PA et al. Differentiation between phyllodes tumor and fibroadenoma using real-time elastography. *Ultraschall Med* 2011; 32 Suppl 2: E75-79. DOI: 10.1055/s-0031-1282024
- 591 Guo X, Loibl S, Untch M et al. Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. *Breast Care (Basel)* 2011; 6: 279-283. DOI: 10.1159/000330946
- 592 Loehberg CR, Strissel PL, Dittrich R et al. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. *Biochem Pharmacol* 2012; 83: 480-488. DOI: 10.1016/j.bcp.2011.11.022
- 593 Strehl JD, Wachter DL, Fasching PA et al. Invasive Breast Cancer: Recognition of Molecular Subtypes. *Breast Care (Basel)* 2011; 6: 258-264. DOI: 10.1159/000331339
- 594 Lux MP, Fasching PA, Loehberg CR et al. Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology. *Geburtshilfe Frauenheilkd* 2011; 71: 1046-1055. DOI: 10.1055/s-0031-1280435
- 595 Burghaus S, Klingsiek P, Fasching PA et al. Risk Factors for Endometriosis in a German Case-Control Study. *Geburtshilfe Frauenheilkd* 2011; 71: 1073-1079. DOI: 10.1055/s-0031-1280436
- 596 Fasching PA, Ekici AB, Adamietz BR et al. Breast Cancer Risk - Genes, Environment and Clinics. *Geburtshilfe Frauenheilkd* 2011; 71: 1056-1066. DOI: 10.1055/s-0031-1280437
- 597 Jud SM, Haberle L, Fasching PA et al. Correlates of mammographic density in B-mode ultrasound and real time elastography. *Eur J Cancer Prev* 2012; 21: 343-349. DOI: 10.1097/CEJ.0b013e32834e3214
- 598 Fasching PA, Heusinger K, Haeberle L et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. *BMC Cancer* 2011; 11: 486. DOI: 10.1186/1471-2407-11-486
- 599 Justenhoven C, Obazee O, Winter S et al. The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. *Breast Cancer Res Treat* 2012; 131: 347-350. DOI: 10.1007/s10549-011-1827-1
- 600 Haiman CA, Chen GK, Vachon CM et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet* 2011; 43: 1210-1214. DOI: 10.1038/ng.985
- 601 Stevens KN, Garcia-Closas M, Fredericksen Z et al. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. *Br J Cancer* 2011; 105: 1934-1939. DOI: 10.1038/bjc.2011.448
- 602 Meier-Meitingner M, Rauh C, Adamietz B et al. Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. *Eur J Surg Oncol* 2012; 38: 44-51. DOI: 10.1016/j.ejso.2011.10.008

- 603 Milne RL, Lorenzo-Bermejo J, Burwinkel B et al. 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. *J Med Genet* 2011; 48: 698-702. DOI: 10.1136/jmedgenet-2011-100303
- 604 Huober J, Fasching PA, Barsoum M et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *Breast* 2012; 21: 27-33. DOI: 10.1016/j.breast.2011.07.006
- 605 Figueroa JD, Garcia-Closas M, Humphreys M et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Hum Mol Genet* 2011; 20: 4693-4706. DOI: 10.1093/hmg/ddr368
- 606 Stevens KN, Vachon CM, Lee AM et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. *Cancer Res* 2011; 71: 6240-6249. DOI: 10.1158/0008-5472.CAN-11-1266
- 607 Milne RL, Goode EL, Garcia-Closas M et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiol Biomarkers Prev* 2011; 20: 2222-2231. DOI: 10.1158/1055-9965.EPI-11-0569
- 608 Untch M, Fasching PA, Konecny GE et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. *J Clin Oncol* 2011; 29: 3351-3357. DOI: 10.1200/JCO.2010.31.4930
- 609 Muller V, Riethdorf S, Rack B et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. *Breast Cancer Res* 2011; 13: R71. DOI: 10.1186/bcr2916
- 610 Burger PH, Goecke TW, Fasching PA et al. [How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]. *Fortschr Neurol Psychiatr* 2011; 79: 500-506. DOI: 10.1055/s-0031-1273360
- 611 Beckmann MW, Brucker C, Hanf V et al. Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. *Onkologie* 2011; 34: 362-367. DOI: 10.1159/000329601
- 612 Goode EL, Chenevix-Trench G, Hartmann LC et al. Assessment of hepatocyte growth factor in ovarian cancer mortality. *Cancer Epidemiol Biomarkers Prev* 2011; 20: 1638-1648. DOI: 10.1158/1055-9965.EPI-11-0455
- 613 Lurie G, Wilkens LR, Thompson PJ et al. Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. *PLoS One* 2011; 6: e20703. DOI: 10.1371/journal.pone.0020703
- 614 Broeks A, Schmidt MK, Sherman ME et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet* 2011; 20: 3289-3303. DOI: 10.1093/hmg/ddr228
- 615 Spurdle AB, Thompson DJ, Ahmed S et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. *Nat Genet* 2011; 43: 451-454. DOI: 10.1038/ng.812
- 616 Koch MC, Adamietz B, Jud SM et al. Breast volumetry using a three-dimensional surface assessment technique. *Aesthetic Plast Surg* 2011; 35: 847-855. DOI: 10.1007/s00266-011-9708-x
- 617 Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. *Clin Pharmacol Ther* 2011; 89: 708-717. DOI: 10.1038/clpt.2011.27
- 618 Pharoah PD, Palmieri RT, Ramus SJ et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clin Cancer Res* 2011; 17: 3742-3750. DOI: 10.1158/1078-0432.CCR-10-3405
- 619 Untch M, Fasching PA, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a

- standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbeoetin alfa in primary breast cancer--results at the time of surgery. *Ann Oncol* 2011; 22: 1988-1998. DOI: 10.1093/annonc/mdq709
- 620 Untch M, von Minckwitz G, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbeoetin alfa in primary breast cancer--outcome on prognosis. *Ann Oncol* 2011; 22: 1999-2006. DOI: 10.1093/annonc/mdq713
- 621 Nickel FT, DeCol R, Jud S et al. Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. *Pain* 2011; 152: 1298-1303. DOI: 10.1016/j.pain.2011.02.005
- 622 Kindla J, Rau TT, Jung R et al. Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. *Cancer Biol Ther* 2011; 11: 584-591. DOI: 10.4161/cbt.11.6.14533
- 623 Milne RL, Gaudet MM, Spurdle AB et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. *Breast Cancer Res* 2010; 12: R110. DOI: 10.1186/bcr2797
- 624 Meier-Meitingner M, Haberle L, Fasching PA et al. Assessment of breast cancer tumour size using six different methods. *Eur Radiol* 2011; 21: 1180-1187. DOI: 10.1007/s00330-010-2016-z
- 625 Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst* 2011; 103: 250-263. DOI: 10.1093/jnci/djq526
- 626 Schrauder MG, Fasching PA, Haberle L et al. Diabetes and prognosis in a breast cancer cohort. *J Cancer Res Clin Oncol* 2011; 137: 975-983. DOI: 10.1007/s00432-010-0960-2
- 627 Heusinger K, Loehberg CR, Haeberle L et al. Mammographic density as a risk factor for breast cancer in a German case-control study. *Eur J Cancer Prev* 2011; 20: 1-8. DOI: 10.1097/CEJ.0b013e328341e2ce
- 628 von Minckwitz G, Untch M, Nuesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Cancer Res Treat* 2011; 125: 145-156. DOI: 10.1007/s10549-010-1228-x
- 629 Kahmann L, Beyer U, Mehlhorn G et al. Mitomycin C in patients with gynecological malignancies. *Onkologie* 2010; 33: 547-557. DOI: 10.1159/000319742
- 630 Bolton KL, Tyrer J, Song H et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet* 2010; 42: 880-884. DOI: 10.1038/ng.666
- 631 Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 2010; 42: 874-879. DOI: 10.1038/ng.668
- 632 Antoniou AC, Wang X, Fredericksen ZS et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 2010; 42: 885-892. DOI: 10.1038/ng.669
- 633 Fletcher O, Johnson N, dos Santos Silva I et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 2143-2151. DOI: 10.1158/1055-9965.EPI-10-0374
- 634 Loehberg CR, Heusinger K, Jud SM et al. Assessment of mammographic density before and after first full-term pregnancy. *Eur J Cancer Prev* 2010; 19: 405-412. DOI: 10.1097/CEJ.0b013e32833ca1f4
- 635 Notaridou M, Quaye L, Dafou D et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. *Int J Cancer* 2011; 128: 2063-2074. DOI: 10.1002/ijc.25554
- 636 von Minckwitz G, Eidtmann H, Loibl S et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the Gepar-Quinto trial. *Ann Oncol* 2011; 22: 301-306. DOI: 10.1093/annonc/mdq350

- 637 Hammer C, Fasching PA, Loehberg CR et al. Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. *Pharmacogenomics* 2010; 11: 943-950. DOI: 10.2217/pgs.10.67
- 638 Schroth W, Hamann U, Fasching PA et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. *Clin Cancer Res* 2010; 16: 4468-4477. DOI: 10.1158/1078-0432.CCR-10-0478
- 639 von Minckwitz G, Rezai M, Loibl S et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. *J Clin Oncol* 2010; 28: 2015-2023. DOI: 10.1200/JCO.2009.23.8303
- 640 Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol* 2010; 28: 2024-2031. DOI: 10.1200/JCO.2009.23.8451
- 641 Azzato EM, Tyrer J, Fasching PA et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. *J Natl Cancer Inst* 2010; 102: 650-662. DOI: 10.1093/jnci/djq057
- 642 Loehberg CR, Jud SM, Haerberle L et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. *Breast Cancer Res Treat* 2010; 121: 101-110. DOI: 10.1007/s10549-010-0845-8
- 643 Lux MP, Fasching PA, Schrauder M et al. The era of centers: the influence of establishing specialized centers on patients' choice of hospital. *Arch Gynecol Obstet* 2011; 283: 559-568. DOI: 10.1007/s00404-010-1398-0
- 644 Bakdash A, Burger P, Goecke TW et al. Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. *Anal Bioanal Chem* 2010; 396: 2469-2477. DOI: 10.1007/s00216-010-3474-5
- 645 Goecke TW, Ekici AB, Niesler B et al. Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy. *Acta Obstet Gynecol Scand* 2010; 89: 7-14. DOI: 10.3109/00016340903322727
- 646 Renner SP, Ekici AB, Maihofner C et al. Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis. *Gynecol Endocrinol* 2009; 25: 726-733. DOI: 10.3109/09513590903159631
- 647 Reulbach U, Bleich S, Knorr J et al. [Pre-, peri- and postpartal depression]. *Fortschr Neurol Psychiatr* 2009; 77: 708-713. DOI: 10.1055/s-0028-1109822
- 648 Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. *JAMA* 2009; 302: 1429-1436. DOI: 10.1001/jama.2009.1420
- 649 Renner SP, Rix S, Boosz A et al. Preoperative pain and recurrence risk in patients with peritoneal endometriosis. *Gynecol Endocrinol* 2010; 26: 230-235. DOI: 10.1080/09513590903159623
- 650 Song H, Ramus SJ, Tyrer J et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 2009; 41: 996-1000. DOI: 10.1038/ng.424
- 651 Jud SM, Fasching PA, Maihofner C et al. Pain perception and detailed visual pain mapping in breast cancer survivors. *Breast Cancer Res Treat* 2010; 119: 105-110. DOI: 10.1007/s10549-009-0485-z
- 652 Milne RL, Benitez J, Nevanlinna H et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. *J Natl Cancer Inst* 2009; 101: 1012-1018. DOI: 10.1093/jnci/djp167
- 653 Gaudet MM, Milne RL, Cox A et al. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 1610-1616. DOI: 10.1158/1055-9965.EPI-08-0745
- 654 Fasching PA, Gayther S, Pearce L et al. Role of genetic polymorphisms and ovarian cancer susceptibility. *Mol Oncol* 2009; 3: 171-181. DOI: 10.1016/j.molonc.2009.01.008
- 655 Wiesner FG, Magener A, Fasching PA et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. *Breast* 2009; 18: 135-141. DOI: 10.1016/j.breast.2009.02.009

- 656 Oppelt P, Renner SP, Strick R et al. Correlation of high-risk human papilloma viruses but not of herpes viruses or Chlamydia trachomatis with endometriosis lesions. *Fertil Steril* 2010; 93: 1778-1786. DOI: 10.1016/j.fertnstert.2008.12.061
- 657 Cupisti S, Fasching PA, Ekici AB et al. Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage. *Arch Gynecol Obstet* 2009; 280: 395-400. DOI: 10.1007/s00404-009-0927-1
- 658 Dunning AM, Healey CS, Baynes C et al. Association of ESR1 gene tagging SNPs with breast cancer risk. *Hum Mol Genet* 2009; 18: 1131-1139. DOI: 10.1093/hmg/ddn429
- 659 Beckmann MW, Bani MR, Loehberg CR et al. Are Certified Breast Centers Cost-Effective? *Breast Care (Basel)* 2009; 4: 245-250. DOI: 10.1159/000229190
- 660 Strissel PL, Ellmann S, Loprach E et al. Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. *Int J Cancer* 2008; 123: 2871-2879. DOI: 10.1002/ijc.23900
- 661 Renner SP, Strick R, Fasching PA et al. Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk. *Am J Obstet Gynecol* 2008; 199: 648 e641-649. DOI: 10.1016/j.ajog.2008.06.015
- 662 Bektas N, Noetzel E, Veeck J et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. *Breast Cancer Res* 2008; 10: R58. DOI: 10.1186/bcr2117
- 663 Rauber D, Mehlhorn G, Fasching PA et al. Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. *Eur J Obstet Gynecol Reprod Biol* 2008; 140: 258-262. DOI: 10.1016/j.ejogrb.2008.05.003
- 664 Bani MR, Beckmann K, Engel J et al. Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. *Breast* 2008; 17: 640-645. DOI: 10.1016/j.breast.2008.05.004
- 665 Bani MR, Lux MP, Heusinger K et al. Factors correlating with reexcision after breast-conserving therapy. *Eur J Surg Oncol* 2009; 35: 32-37. DOI: 10.1016/j.ejso.2008.04.008
- 666 Laessig D, Stemmler HJ, Vehling-Kaiser U et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. *Oncology* 2007; 73: 407-414. DOI: 10.1159/000136796
- 667 Fasching PA, Kollmannsberger B, Strissel PL et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. *J Cancer Res Clin Oncol* 2008; 134: 1079-1086. DOI: 10.1007/s00432-008-0387-1
- 668 Schrauder M, Frank S, Strissel PL et al. Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. *J Cancer Res Clin Oncol* 2008; 134: 873-882. DOI: 10.1007/s00432-008-0355-9
- 669 Siemer J, Theile O, Larbi Y et al. Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa. *Am J Trop Med Hyg* 2008; 78: 323-327.
- 670 Binder H, Dittrich R, Hager I et al. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. *Reproduction* 2008; 135: 107-116. DOI: 10.1530/REP-07-0276
- 671 Fasching PA, Loehberg CR, Strissel PL et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. *Breast Cancer Res Treat* 2008; 112: 89-98. DOI: 10.1007/s10549-007-9822-2
- 672 Fasching PA, Nicolaisen-Murmann K, Lux MP et al. Changes in satisfaction in patients with gynaecological and breast malignancies: an analysis with the Socio-Economic Satisfaction and Quality of Life questionnaire. *Eur J Cancer Care (Engl)* 2007; 16: 508-516. DOI: 10.1111/j.1365-2354.2007.00784.x
- 673 Fasching PA, Bani MR, Nestle-Kramling C et al. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. *Eur J Cancer Prev* 2007; 16: 216-224. DOI: 10.1097/CEJ.0b013e32801023b3
- 674 Beckmann MW, Bani MR, Fasching PA et al. Risk and risk assessment for breast cancer: molecular and clinical aspects. *Maturitas* 2007; 57: 56-60. DOI: 10.1016/j.maturitas.2007.02.013

- 675 Fasching PA, Thiel F, Nicolaisen-Murmann K et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. *Support Care Cancer* 2007; 15: 1277-1284. DOI: 10.1007/s00520-007-0231-1
- 676 Bani HA, Fasching PA, Lux MM et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. *Patient Educ Couns* 2007; 66: 311-318. DOI: 10.1016/j.pec.2007.01.004
- 677 Skiba D, Mehlhorn G, Fasching PA et al. Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer. *Anticancer Res* 2006; 26: 4921-4926. DOI: 10.1055/s-2006-952200
- 678 Fasching PA, Beckmann MW. Hormones and genetics caught in the crossfire of preventive medicine. *Lancet Oncol* 2007; 8: 5-6. DOI: 10.1016/S1470-2045(06)70987-1
- 679 Ackermann S, Lux MP, Fasching PA et al. Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. *Eur J Cancer Prev* 2006; 15: 474-479. DOI: 10.1097/01.cej.0000220628.62610.ea
- 680 Strick R, Ackermann S, Langbein M et al. Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta. *J Mol Med (Berl)* 2007; 85: 23-38. DOI: 10.1007/s00109-006-0104-y
- 681 Fasching PA, von Minckwitz G, Fischer T et al. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. *Breast Cancer Res Treat* 2007; 101: 95-104. DOI: 10.1007/s10549-006-9272-2
- 682 Fasching PA, Heusinger K, Loehberg CR et al. Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. *Eur J Radiol* 2006; 60: 398-404. DOI: 10.1016/j.ejrad.2006.08.002
- 683 Kreis H, Loehberg CR, Lux MP et al. Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignancies. *Eur J Surg Oncol* 2007; 33: 39-43. DOI: 10.1016/j.ejso.2006.08.003
- 684 Glaeser M, Niederacher D, Djahansouzi S et al. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery. *Anticancer Res* 2006; 26: 735-744.
- 685 Renner SP, Strick R, Oppelt P et al. Evaluation of clinical parameters and estrogen receptor alpha gene polymorphisms for patients with endometriosis. *Reproduction* 2006; 131: 153-161. DOI: 10.1530/rep.1.00787
- 686 Ackermann S, Renner SP, Fasching PA et al. Awareness of general and personal risk factors for uterine cancer among healthy women. *Eur J Cancer Prev* 2005; 14: 519-524. DOI: 10.1097/00008469-200512000-00005
- 687 Lux MP, Ackermann S, Bani MR et al. Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer. *Eur J Cancer Prev* 2005; 14: 503-511. DOI: 10.1097/00008469-200512000-00003
- 688 Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. *J Mol Med (Berl)* 2006; 84: 16-28. DOI: 10.1007/s00109-005-0696-7
- 689 Pohls UG, Fasching PA, Beck H et al. Demographic and psychosocial factors associated with risk perception for breast cancer. *Oncol Rep* 2005; 14: 1605-1613.
- 690 Lux MP, Bani MR, Fasching PA et al. [Prophylactic surgery of mammary and ovarian carcinoma]. *Chirurg* 2005; 76: 1145-1154. DOI: 10.1007/s00104-005-1100-4
- 691 Heusinger K, Lohberg C, Lux MP et al. Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*. *Breast Cancer Res Treat* 2005; 94: 17-23. DOI: 10.1007/s10549-005-6653-x
- 692 Loehberg CR, Lux MP, Ackermann S et al. Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used? *Anticancer Res* 2005; 25: 2519-2525.
- 693 Lux MP, Ackermann S, Nestle-Kramling C et al. Use of intensified early cancer detection in high-risk patients with familial breast and ovarian cancer. *Eur J Cancer Prev* 2005; 14: 399-411. DOI: 10.1097/00008469-200508000-00014

- 694 Pohls UG, Renner SP, Fasching PA et al. Awareness of breast cancer incidence and risk factors among healthy women. *Eur J Cancer Prev* 2004; 13: 249-256. DOI: 10.1097/01.cej.0000136718.03089.a5
- 695 Beckmann MW, Strick R, Strissel PL et al. Aspects of molecular diagnostics and therapy in obstetrics and gynecology. *Expert Rev Mol Diagn* 2003; 3: 279-287. DOI: 10.1586/14737159.3.3.279
- 696 Brumm C, Fasching PA, Beckmann MW. [Treatment of endometrial carcinoma - evidence based criteria]. *Zentralbl Gynakol* 2002; 124: 32-35. DOI: 10.1055/s-2002-20307